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1.1 SUSTAINED RELEASE DRUG DELIVERY SYSTEM (Bankar G.S and   
Rhodes C.T., 2009; Brahmankar D.M and Jaiswal S.B., 2005; Chein Y.W., 2002) 
The goal of a sustained release dosage form is to maintain therapeutic blood or 
tissue levels of the drug for an extended and specified period of time. This is generally 
accomplished by attempting to obtain "zero-order" release from the dosage form. Zero-
order release constitutes drug release from the dosage form which is independent of the 
amount of drug in the delivery system (i.e. a constant release rate). Sustained-release 
systems generally do not attain this type of release and usually try to mimic zero-order 
release by providing drug in a slow first-order fashion (i.e., concentration release 
dependent). Systems that are designated as prolonged release can also be considered as 
attempts at achieving sustained-release delivery. 
The term “Controlled- release drug product” has been used to describe various types 
of oral extended release rate dosage forms, including sustained release (SR), sustained 
action, prolonged action, long action, and retarded release. These terms for extended 
release dosage forms were introduced by drug companies to reflect a special design for 
producing an extended release (ER) dosage form or used as a marketing term In the last 
two-three decades interest in sustain release drug delivery systems is remarkably 
increasing. This has been due to various factors .  
1. INTRODUCTION 
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 Developing new drug entities. 
 Expiration of international patents 
 Discovery of new polymeric materials suitable for prolonging the drug release. 
 Need of therapeutic efficacy and safety achieved by sustained release drug delivery. 
The subject of sustain release has been reviewed by various authors. Several books 
have been published on it. These reviews and books provide not only the mechanisms and 
technology of production of dosage forms but also the information on clinical evidence and 
performance. 
There are many definitions of sustained release but the simplest definition is “Any 
drug or dosage form or medication that prolongs the therapeutic activity of drug’’. The 
overall objective is that, once the drug-carrier material has been injected or otherwise 
implanted or taken orally into the body, the drug is released at a predetermined rate for 
some desired period of time. Controlled release technology is relatively new field and as a 
consequence, research in this field has been extremely fertile and has produced many 
discoveries.   
Non-immediate release delivery systems may be divided conveniently into 4 
categories, 
    A. Sustained release  
                     a) Controlled release 
              b) Prolonged release 
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     B. Delayed release                        
     C.   Site- specific release 
     D.   Receptor release 
 
Sustained- release systems includes any drug delivery system that achieves slow 
release of drug over an extended period of time 
 
Delayed – release systems are those that use repetitive, intermittence dosing of a 
drug from one or more immediate release units incorporated into a single dosage forms to 
make delayed action. Example: Repeat- action tablets and capsules, enteric coated tablets 
where timed release achieved by a barrier coating..  
 
Controlled release systems are those systems which are successful maintaining 
constant drug levels in blood or target release (i.e.) release rate of drug occurs in controlled 
manner.  
 
Prolonged released systems only extends the duration of action and drug release 
that achieved by conventional drug delivery. 
 
Site specific and receptor release refers to targeting of drug directly to a certain 
biological location. In the case of site- specific release, the target is a certain organ or 
tissue, for receptor release, the target is the particular receptor for a drug within an organ or 
tissue. 
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Figure.1 Plasma concentration Vs time profile from conventional multiple and single doses     
               of sustained release drug delivery formulations. 
 
 
Control release system differs from Sustain release system which simply prolongs the 
drug release and hence plasma drug levels for an extended period of time (i.e. not 
necessarily at a predetermined rate). Thus the chief objective of most products should be 
controlled delivery to reduce dosing frequency to an extent that once daily dose is sufficient 
for therapeutic management through a uniform plasma concentration at steady state. 
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1.1.1 Advantages of sustained release drug delivery system (Bankar G.S and Rhodes               
         C.T., 2009; Chein Y.W., 2002) 
       Some advantages are as follows 
1. Reduction in dosing frequency. 
2. Reduction in GI irritation and other side effects. 
3. Avoidance of night time dosing. 
4. Reduced fluctuation in circulating drug levels. 
5. Increased patient convenience and compliance. 
6. More uniform effect. 
7. Maximum utilization of drug. 
8. Reduction in health care cost through improved therapy. 
9. Improve bioavailability of some drugs. 
1.1.2 Disadvantages sustained drug delivery system  
1. Decreased systemic availability in comparison to immediate release conventional 
dosage form.  
2. Poor in vitro-in vivo correlation. 
3. Higher cost of formulation. 
4. Possibility of dose dumping. 
5. Retrival of drug is difficult in case of toxicity, poisoning, or hypersensitivity 
reactions. 
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1.2  FUNDAMENTALS FOR A DRUG TO BE SUITABLE FOR DESIGN OF ORAL  
 SUSTAINED RELEASE DOSAGE FORM         (Bandyopadhyay A .K., 2008) 
       Some characteristics make a drug more suitable for extended release dosing, such as- 
1. Moderate unit dose 
2.  Elimination half-life between 2 to 8 hours. 
3.  Broader therapeutic index. 
4. Significant extent of absorption in GIT. 
5. Minimal first-pass clearance. 
6. Optimum solubility characteristics 
1.3 FACTORS INFLUENCING OF SUSTAINED RELEASE PRODUCTS               
(Bandyopadhyay A .K., 2008) 
Oral sustained release drug delivery is the most widely utilized route of 
administration among all the routes that have been explored for the systemic delivery of 
drugs via various pharmaceutical products in different dosage forms. Irrespective of their 
mode of delivery (immediate, sustained or controlled release) and the design of dosage 
forms (either solid or liquid) they must be developed within the intrinsic characteristics of 
GIT physiology. A number of variables such as drug properties, route of delivery, target 
sites, duration of therapy, the disease state and patient variables must be considered. The 
formulation and performance of sustained release products are greatly influenced by the 
physicochemical and biological properties of drug.   
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1.4 PROPERTIES RELEVANT TO SUSTAINED RELEASE  DRUG 
FORMULATIONS (Banker G.S and Rhodes C.T., 2009; Robinson J.R and   
 Lee V.H.L., 1987) 
During design of sustained release delivery systems, variables such as the route of 
drug delivery, the type of delivery system, the disease being treated, the patient, the length 
of therapy and the properties of the drug, are considered.  These properties are classified as, 
     A) Physicochemical and 
                                    B) Biological properties 
These properties have the greatest effect on the behavior of the drug in the delivery 
system and in the body. There is no clear-cut distinction between these two categories since 
the biological properties of a drug are a function of its physicochemical properties. By 
definition, physicochemical properties are those that can be determined from in vitro 
experiments and biological properties will be those that result from typical pharmacokinetic 
studies of the absorption, distribution, metabolism, and excretion (ADME) characteristics of 
a drug and those resulting from pharmacological studies.  
 
A) Physicochemical Properties 
a) Dose Size 
b) Aqueous Solubility and pKa  
c) Partition Coefficient 
d) Drug Stability 
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e) Molecular Size and Diffusivity 
f) Drug Protein Binding 
B) Biological Properties 
                 a) Absorption 
 b) Distribution 
 c) Metabolism 
           d) Elimination and Biological Half-Life 
 e) Margin of Safety (Toxicity). 
A. Physiochemical properties 
a) Dose size: For orally administered drugs, there is an upper limit to the bulk size of 
the dose to be administered. In general, a single dose of 0.5 – 11.0 gm for conventional 
dosage form is considered maximal. 
b) Aqueous Solubility: Extremes in aqueous solubility are under desirable in the 
preparation of a SR product. For drug with low water solubility, it will be difficult to 
incorporate into a SR formulation. The lower limit of solubility for such product has 
been reported to be 0.1 mg/ml. 
c) Partition Co-efficient: drug that are very lipid soluble or water soluble i.e. extremes 
in partition co-efficient, will demonstrate either low flux in to the tissues or rapid flux 
followed by accumulation in the tissues. Both extremes are undesirable for a SR system 
E.g.: Phenothiazines class of compounds is highly lipid soluble. 
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d) Drug Solubility: since most oral SR systems, by necessity are designed to release 
their contents over much of the length of the GIT, drugs which are unstable in the 
environment of the intestine might be difficult to formulate into prolonged release 
systems.  
E.g.: Propanthdine and Probanthine. 
B. Biological properties 
           a) Absorption:  Drugs that are slowly absorbed or absorbed with variable absorption 
rate are poor candidates for SR systems. For oral dosage forms the lower limit on the 
absorption rate constant is in the range of 0.17 to 0.23 hr -1(assuming GI transit time 
          of 8-12 hr -1). 
   b) Metabolism: Drugs that are significantly metabolized, especially in region of small 
intestine, can show decreased bioavailability from SR dosage forms, because less total 
drug is presented to enzymatic process during a specific period. This allows more 
complete conversion of drug to its metabolite. 
   c) Therapeutic Index:  Drugs with a narrow therapeutic range which require precise 
control over the blood levels of the drug are unsuitable for SR dosage forms. 
   d) Half Life: The biological half life and duration of action of drug obviously plays a 
major rule in considering a drug for SR systems. Drugs with a very short half life 
   (>2 hr) require large amounts of drug to maintain sustained effects and drugs with 
longer life (<8hrs) because their effects are already sustained.   
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1.5 POLYMERS USED IN SUSTAINED RELEASE PHARMACEUTICAL  
       DOSAGE FORMS                                                                    (Jain N.K., 2008) 
 Polymers are complex and giant molecules known as macromolecules consisting of     
      many repeating units and are formed by process called as polymerization. In general,   
     polymers Can be classified into 3 categories as follows 
Polymer Classification 
   
 
Natural        Synthetic                   Semi-synthetic  
 Xanthum Gum, Chitosan,         Polymethacrylate Derivatives              Cellulose, HPMC. 
 Sodium Aliginate. 
 
Table1. Classification of Polymers used in Oral Sustained Release Drug Delivery Systems  
             according to their characteristics. 
S. No. 
Polymer 
Characteristics 
Material 
1. Insoluble, inert 
Polyethylene, Polyvinyl chloride, Methyl 
acrylates-methacrylate copolymer. 
2. Insoluble, erodible 
Carnauba wax, Stearyl alcohol, Stearic acid, 
Polyethylene glycol. Castor wax, Polyethylene 
glycol, Monostearate triglycerides. 
3. Hydrophilic 
Methylcellulose (400cps, 4000cps), 
Hydroxypropylmthylcellulose (HPMC), Sodium 
alginate, Galactomannose. 
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1.6 PRINCIPLE BEHIND SUSTAINED DRUG RELEASE (Bankar G.S and Rhodes 
C.T., 2009; Brahmankar D.M and Jaiswal S.B., 2005; Robinson J.R and Lee V.H.L., 
1987) 
Dissolution and diffusion controlled systems have classically been of primary 
importance in oral delivery of medication because of their relative ease of production and 
cost compared with other methods of sustained or controlled delivery.  
 The classification of such systems is as follows: 
1. Diffusion controlled systems. 
2. Dissolution controlled systems. 
3. Dissolution and Diffusion controlled systems. 
4. Osmotically controlled systems. 
5. Ion exchange systems.   
 
 
1. Diffusion Controlled  Systems 
Diffusion systems are characterized by the release rate being dependent on its 
diffusion through an inert membrane barrier. Usually this barrier is an insoluble polymer. 
In general two types of sub classes of diffusion systems are recognized they are  
a. Reservoir devices.  
b. Matrix devices. 
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a. Reservoir devices 
Reservoir devices are characterized by a core drug reservoir surrounded by a 
polymeric membrane.. 
 
Advantages 
1. Zero order delivery is possible. 
2. Release rate variable with polymer type. 
 
Disadvantages 
1. Potential toxicity if system fails. 
2. System must be physically removed from implant sites. 
3. Difficult to deliver high molecular weight compounds. 
4. Generally increased cost per dosage units. 
 
b. Matrix Devices 
It contains of drug dispersed homogeneously throughout a polymer matrix. In this 
model, drug in the outside layer exposed to bath solution is dissolved first and then diffuses 
out of the matrix. The following equation describe the rate of release of drug dispersed in 
an inert matrix system have been derived by Higuchi. 
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Dm/dh  = Codh – Cs/2. 
Where,  dm = Change in the amount of drug released per unit area. 
   dh      = Change in the thickness of the zone of matrix that have been   
                                               depleted of drug.                              
               Co      =  Total amount of drug in unit volume of matrix. 
                    Cs      = Saturated concentration of drug within the matrix. 
Advantages 
1. Can deliver high molecular weight compounds. 
2. Easier to produce than reservoir devices. 
Disadvantages 
1. Removal of remaining matrix is necessary for implanted systems. 
2. Cannot obtain zero order release. 
Diffusion Rate Modifications 
 Modification of the following will change the rate of diffusion 
(a) Thickness of the separating layer,  
(b) Porosity 
(c) Partition coefficient, 
(d) Modification of the diffusion co-efficient. 
(e) Modification of efficient molecular size. 
(f) Modification of viscosity. 
(g) Modification of concentration. 
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2. Dissolution-controlled Systems 
 Drug with a slow dissolution rate will demonstrate sustaining properties, since the 
release of the drug will be limited by rate of dissolution. This being the case, SR 
preparations of drugs could be made by decreasing their dissolution rate. This includes 
preparing appropriate salts or derivatives, coating the drug with a slowly dissolving 
material, or incorporating it into a tablet with a slowly dissolving carrier. 
 The dissolution process at steady state, is described by Noyes-Whitney equation, 
  dc/dt = KDA(Cs-C) = D/h A(Cs-C) 
           Where,  
dc/dt  = Dissolution rate. 
  KD = Diffusion co-efficient 
 A         = surface area of the dissolving solid
 
  Cs = Saturation solubility of the solid. 
  C = Concentration of solute in bulk solution. 
  H = Thickness of diffusion layer. 
Principles of dissolution rate modification 
 The following are may affect dissolution rate modification of   
(a) Solubility,  
(b) Specific area, 
(c) Particle shape and surface structure, 
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(d) Dissolution  
(e) Crystallographic modification. 
3. Dissolution and Diffusion - Controlled release system 
Normally, therapeutic systems will never be dependent on dissolution only or 
diffusion only. In practice, the dominant mechanism for release will over shadow other 
processes enough to allow classification as either dissolution rate limited or diffusion 
controlled.  
 
The mechanism of release from simple erodible slabs, cylinders and spheres has 
been described by Hopenberg are described as  
Mt/M = 1 - (1- Kot/Co a)n 
Where,   n = 2 for cylinder and  
n = 1 for a slab. 
a = Radius of sphere or cylinder or half height of a slab. 
Mt  = Mass of drug release at time t 
M = Mass released infinite time. 
 
Advantages 
1. Easier to produce than reservoir devices. 
2. Can deliver high – molecular weight compounds. 
3. Removal from implant sites is not necessary. 
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Disadvantages 
1. Difficult to control kinetics owning to multiple process of release. 
2. Potential toxicity of degraded polymer must be considered. 
4. Osmotically controlled systems  
 This device is fabricated as tablet that contains water soluble osmotically active 
drug, of that was blended with osmotically active diluents by coating the tablet with a 
cellulose triacetate barrier which functions as a semi permeable membrane. A laser is used 
to form a precision orifice in the barrier, through which the drug is released due to 
development of osmotic pressure difference across the membrane, when this was kept in 
water. 
 
 
 
Figure.2 Osmotically controlled release systems. 
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      5.  Ion Exchange Systems 
 These are salts of cationic or anionic exchange resins or insoluble complexes in 
which drug release results from exchange of bound drug ions that are normally present in 
GI fluids. 
 
1.7 MATRIX SYSTEMS (Bankar G.S and Rhodes C.T., 2009; Brahmankar D.M and  
     Jaiswal S.B., 2005; Robinson J.R and Lee V.H.L., 1987) 
 Easy to manufacture 
 Versatile, effective, low cost. 
 Can be made to release high molecular weight compounds. 
 Since the drug is dispersed in the matrix system, accidental leakage of the total 
drug component is less likely to occur, although occasionally, cracking of the 
matrix material can cause unwanted release. 
 
1.7.1 Different types of Matrix tablets 
1) Hydrophilic matrices 
2) Hydrophobic matrices 
3) Plastic matrices 
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1) Hydrophilic Matrices  
. The matrix tablet may be prepared by direct compression of the blend of active 
ingredient and certain hydrophilic carriers, or from a wet granulation containing a drug and 
hydrophilic matrix materials. The hydrophilic matrix requires water to activate the release 
mechanism and enjoys several advantages, including ease of manufacture and excellent 
uniformity of matrix tablets. Drug release is controlled by a gel diffusion barrier that is 
formed and/or tablet erosion. The effect of formulation and processing variables on drug 
release behavior from compressed hydrophilic matrices has been studied by a number if 
investigators and can be summarized as follows: 
 
 
 The matrix building material with fast polymer hydration capacity is the best choice 
to use in the hydrophilic matrix tablet formulations. 
 
 Generally, reduced particle size of hydrophilic polymer ensures rapid hydration and 
gel formation, leading to good controlled release. 
 
 
 For Some hydrophilic matrix building materials, PH may affect the viscosity of the 
gel, which forms on the surface, and its subsequent rate of hydration. 
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Figure.3 Drug release Mechanism of Matrix tablet. 
 Viscosity characteristics of polymers are of great importance in determining the 
final release properties of the matrix tablet. Generally, the drug release rate is 
slower for a higher viscosity grade polymer. 
 
 Commonly, water-soluble excipients in the matrix tablet can increase drug release.. 
 
 
 
2) Hydrophobic Matrices (Fat-Wax matrix tablets) 
     The drug can be incorporated into a fat-wax granulation by spray congealing in 
air, blend congealing in an aqueous media with or without the aid of surfactant and spray 
drying technique. The mixture of active ingredients, waxy materials and fillers can also be 
converted into granules by compacting with a roller compactor or by direct compression. 
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Enteric materials such as cellulose acetate phthalate, polyvinyl acetate phthalate, 
methacrylate copolymers, zein, and shellac may be used to prepare matrix tablets with 
somewhat a similar release mechanism. The surface erosion of the fat-wax matrix depends 
upon the nature and percent of fat-wax materials and extenders in the matrix. Other factors 
such as drug particle size and drug concentration affect release of the drug from the tablet 
matrix. 
 
3)  Plastic Matrix Tablet 
. Commonly used plastic materials are polyvinyl chloride, polyethylene, polyvinyl acetate/ 
vinyl chloride copolymer, acrylate/methyl methacrylate copolymer, ethyl cellulose, 
cellulose acetate. Plastic matrix tablets, in which the active ingredient in embedded in a 
tablet with coherent and porous skeletal structure, can be easily prepared by direct 
compression of the drug with plastic material. Drug solubility in the dissolution medium 
and in the matrix has the release factors can be summarized as follows: 
 The release rate increases as the solubility increases. 
 The release rate increases as the drug concentration increases. 
 It is possible to modify release rate by inclusion of hydrophilic or hydrophobic 
additives to the matrix. The decrease in the release rate on addition of hydrophobic 
substance may be due to decreased wettability of the matrix. 
 The release rate from plastic matrix tablets could be decreased by exposure to the 
acetone vapour without changing the release mechanism. 
 
                                                                               
  ACYCLOVIR SUSTAINED RELEASE MATRIX TABLETS                      INTRODUCTION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 21 
 
1.8  FACTORS INFLUENCING SELECTION OF POLYMER  
(Rowe R.C., et   al., 2003) 
Generally rheological behavior and possible interactions with the drug and other 
components of the dosage form are major factors to be considered. Other factors are, 
a) Physicochemical Compatibility 
 The physicochemical type of polymers and other ingredients in the system must be 
mutually compatible. Knowledge of charge on the particle surface is helpful in anticipating 
changes in the stability character. 
b) Biological Compatibility 
It is obvious that certain polymeric agents will be removed from consideration 
depending on the route of administration or application. The vulnerability of materials of 
natural organ to microbiological attack is often cited. 
1.9   TABLETS               (Bankar G.S and Rhodes C.T., 2009; Lachman L, et al., 1991) 
  Tablets remain popular as dosage forms because they are advantageous to both the 
manufacturer and the patient. 
1.9.1 Advantages of tablet dosage form 
 They are a unit dose form. 
 Their cost is lowest. 
 They are in general the easiest and cheapest to package and ship of all oral dosage 
forms. 
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 Product identification is potentially the simplest and cheapest, requiring no 
additional processing steps when employing as embossed or monogrammed punch 
face. 
 They may provide the greatest ease of swallowing. 
 They are better suited to large-scale production  
 They have the best combined properties of chemical mechanical and microbiologic 
stability of all the oral forms. 
1.9.2 Disadvantages of tablets 
 Some drugs resist compression into dense compacts. 
 Drugs with poor wetting, slow dissolution properties, intermediate to large dosages, 
optimum absorption high in the gastrointestinal tract, or any combination of these 
features may be difficult or impossible to formulate and manufacture as a tablet. 
 Bitter – tasting drugs that are sensitive to oxygen or atmospheric moisture may 
require encapsulation or entrapment prior to compression, or the tablets may require 
coating. In such cases, the capsule may offer the best and lowest cost approach. 
1.9.3   Formulation of tablets  
. The first group contains those that help to impart satisfactory processing 
characteristics to the formulation. These include diluents, binders, glidants and lubricants. 
The second group of added substances help to give additional desirable physical 
characteristics to the finished tablet is disintegrants, colors, flavors and sweetening agents 
and polymers.  
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Tablet ingredients maybe divided conveniently in to following categories. 
 Diluents 
 Binders. 
 Disintegrants 
  Lubricants and glidants 
 Organoleptic agents. 
 
a) Diluents 
In the single dose, the active ingredient in small and an inert substance  is added to 
increase the bulk to make the tablet a practical size for compression like dicalcium 
phosphate, calcium sulfate, lactose, cellulose, kaolin, etc. Certain diluents such as mannitol, 
lactose, sorbitol, and inositol, when present in sufficient quantity, disintegration in the 
mouth by chewing. 
 
b)  Binders 
Agents used to impart cohesive qualities to the powdered material are referred 
to as binders or granulators. Materials commonly used as binders include starch, gelatin 
and sugars such as sucrose, glucose, dextrose, molasses and lactose. Natural and 
synthetic gums that have been used include acacia, sodium alginate and extract of 
mucilage, carboxymethyl cellulose, methyl cellulose and polyvinylpyrrolidone.  
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c) Disintegrant 
A disintegrant is added to most tablet formulations a break up or disintegration of 
the tablet when it contacts water in the gastrointestinal tract.. Tablet fragmentation may be 
critical to the subsequent dissolution of the drug and to the attainment of satisfactory drug 
bioavailability. Starch USP and various starch derivatives are the most common 
disintegrating agents.  
 
        d)  Lubricants and glidants 
Lubricants are included in formulations to reduce wear and friction in the 
equipment during operation. Some of the lubricants also aid in the enhancing the flow 
properties of the powders during mixing. Lubricants include calcium stearate, magnesium 
stearate, mineral oil (light), polyethylene glycol, sodium stearyl fumarate, purified stearic 
acid, talc, vegetable oil (hydrogenated) and zinc stearate. 
Glidants are the substances that improve the flow characteristics of a powder 
mixture. These materials are always added in the dry state just prior to compression (i.e. 
during lubrication step). Colloidal silicon dioxide is most commonly used glidants and 
generally used in low concentration of 1% or less and Talc is also used. 
  e)  Organoleptic agents 
The use of colors and dyes in tablet making has served three purposes over the 
years, distinguishing off- color drugs, product identification, and production of a more 
elegant product. Flavors are usually limited to chewable tablets or other tablets intended to 
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dissolve in the mouth.. The use of sweeteners is primarily limited to chewable tablets to 
exclude or limit the use of sugar in the tablet 
1.10. Introduction to Antiviral:                                                   (Don A. Ballington., 2005) 
 
There are fewer medications to treat viral infections than there are for bacterial 
infections. Part of the difficulty is that antibiotics often disrupt a cellular process that is unique 
to the bacterium being treated. This allows dosing of the medication without causing toxicity to 
the patient. However, because viruses use the cellular processes of the host to function and 
replicate, medications that block the life cycle of the virus are often toxic to the patient.  Thus, 
the antiviral have been formulated to search and destroy the virus cell lodged in its host cell 
without interfering with the host cell's normal function. Antiviral are among the drugs of 
choice for the following conditions. Cytomegalovirus (CMV) retinitis 
 Genital herpes 
 
 Herpes simplex 
 
 Herpes simplex keratitis 
 
 Herpes zoster (shingles) 
 
 Influenza prophylaxis 
 
 Organ transplantation 
 
 Varicella (chicken pox) 
 
1.11. Viruses and Their Characteristics: 
 
A virus is a minute infection agent which is much smaller than a bacterium. Unlike a 
bacterium, a virus does not have all the components of a cell and thus it is able to replicate 
only within a living host cell. Viruses, among the most common infectious agents in 
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humans, replicate by using the host cells' metabolic processes. A virus can infect a spectrum 
of cells including animal, plant, or bacteria cells. Most common viruses are spread by one of the 
following routes. 
 Direct contact 
 
 Ingestion of contaminated food and water 
 
 Inhalation of airborne particles 
 
The individual virus particle, a virion, consists of nucleic acid (nucleoid), either 
deoxyribonucleic   acid  (RNA)  (but  not  both),  and  a  protein  shell  (capsid)  that 
surrounds and protects the nucleic acid. Depending on the virus, the capsid may be converted 
with spikes that attach to the host cell. Binding of the spikes to membrane receptors simulates a 
process whereby the cell engulfs the virus. A virus without an envelope covering the capsid is 
called a naked virus. 
 
1.12. Stages of Viral Infection: 
 
Within the body, viral infection takes place at the cellular level and in the following 
stages. 
1. The virus attaches to a cell receptor 
 
2. The cell membrane indents and closes around the virus (endocytosis) and thus the      
    virus penetrates the cell 
3. The virus escapes into cytoplasm 
 
4. The virus uncoats, sheds its covering, and presents its DNA or RNA to cell nucleus. 
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1.13. Viral Classification: 
 
Viral infections are classified in two ways.  The first classification is  the duration or 
length of time they have been present in the body as well as their severity. The second 
classification measures the extent of the infections within the body or the parts of the body that 
are affected. 
1.13.1. Viral Duration and Severity: 
 
With  the  classification  of  duration  and  severity  there  are  three  categories: 
acute,  chronic,  and slow.  An acute viral infection quickly resolves with no latent 
infection.   Examples   include   the   common   cold,   influenza,   and   various   other 
respiratory tract infections. A chronic viral infection has a protected course with long 
periods of remission interspersed with reappearance, such as the herpes virus infection. A 
slow viral infection maintains a progressive course over months or years, with  
cumulative  damage  to  body  tissue,  ultimately  ending  in  the  host's  death. Examples 
of this type of destructive viral infection include human immunodeficiency virus (HIV) 
and diseases affecting the central nervous system (CNS). 
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1.14. Viral Life Cycle:                                                                        (Ilango K., 2005) 
             Viral  life  cycle  varies  with  species,  but  they  all  share  a  general  petten  can  be 
sequenced as follows: 
Virus 
Adsorption 
Penetration 
Uncoating 
Transcription 
Reverse transcriptase 
Translation 
Assembly 
Release 
 
 
 
Figure 4: Pathology of viral life cycle 
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General approaches for treating the virus infection by antiviral agents are: 
 
 
 
Figure 5: Various classes of anti-viral agents against the virus life cycle 
a) Interference of virus attachment to the host 
b) Inhibition of virus associated enzymes 
c) Inhibition of transcription process 
d) Inhibition of translation process 
 
e) Interference with viral regulatory process 
 
f) Interference with glycosylation, phosphorylation, etc., 
g) Interference with viral assembly of viral protein 
h) Interference with release of virus from cell surface membrane. 
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Table 2: List of some RNA virus types together with disease that they cause 
 
RNA Viruses 
Virus Disease 
Picornaviruses Polio, Hepatitis A 
Rhinovirus Commen cold, Pneumonia 
Togavirus Rubella, Encephalitis 
Flavirus Yellow fever, Dengue fever, St.Louis encephalitis 
Bunyaviruses Encephalitis, Hemorrhagic fever 
Rhabdoviruses Vesicular stomatitis 
Myxoviruses Mumps, Measles 
Reoviruses or Rotaviruses Diarrhea 
Arenaviruses Lymphatic choriomeningitis 
Retroviruses Human immunodeficiency syndrome (HIV) 
 
 
Table 3: List of some DNA virus types together with disease that they cause 
 
DNA Viruses 
Virus Disease 
Herpes viruses Herpes, Cold sores 
Papovaviruses Polyoma, warts 
Adenoviruses Respiratory complications 
Poxvirus Smallpox 
Parvirus Canine distemper 
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Herpes simplex virus (HSV) is a member of family of herpes viridae, a DNA virus. 
There are two types of Herpes Simplex Viruses (HSV). viz HSV type 1 and type 2. HSV type 
1 is the herpes virus that is usually responsible for cold sores of the mouth, the so called “fever 
blisters”. HSV type 2 is the one that most commonly causes genital herpes. The infection 
causes painful sores on the genitals in both men and women.. Currently the treatments 
available for herpes simplex are conventional tablets and topical gel for application on 
outbreaks. The drugs that are commonly used for herpes simplex are Acyclovir, Valaclovir 
and Famciclovir. 
Acyclovir, the first agent to be licensed for the treatment of herpes simplex virus 
infections, is the most widely used drug for infections such as cutaneous herpes, genital 
herpes, chicken pox, varicella zoster infections. Acyclovir is currently marketed as capsules 
(200 mg), tablets (200, 400 and 800 mg) and topical ointment. Oral acyclovir is mostly used as 
200 mg tablets, five times a day. In addition, long term administration of acyclovir (6 month 
or longer) is required in immune compromised to patient with relapsing herpes simplex 
infection. The presently available conventional therapy is associated with a number of 
drawbacks such as highly variable absorption and low bioavailability (10–20%) after oral 
administration. Furthermore, with increase in dose, there is decrease in bioavailability. 
Moreover, because the mean plasma half life of the drug is 2.5 hours, five times a day 
administration is required. In order to make oral therapy of acyclovir more patients 
2.1 NEED OF THE PRESENT WORK 
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compliant there is a need of using different approaches like matrix tablets, nanoparticle and 
polymeric films. 
Among the many techniques used for modulating the drug release profile, the most   
commonly used method is embedment of the drug into a polymer matrix.  
The matrix may be formed by either dissolving or dispersing the drug uniformly in the 
polymer mass.  Such polymer matrices can give  
 Desirable release profiles,  
 Cost effective manufacturing method and also  
 Broad regulatory acceptance.  
Hence, in the present work, an attempt is made to develop sustained-release matrix tablets 
of Acyclovir, with the use of various natural polymers for their sustaining effect. Direct 
compression technique is used for tablet formulation along with the addition of suitable 
additives by using of natural polymers of Sodium Alginate and Chitosan. 
ACYCLOVIR SUSTAINED RELEASE MATRIX TABLETS                    NEED AND OBJECTIVES 
Adhiparasakthi College of Pharmacy, Melmaruvathur      Page 33 
 
 
 
 
 
To design of sustained release matrix tablet of Acyclovir that will help in 
releasing only small quantities of drug over a prolonged period of time.  
 To study the effect of polymers and polymer concentration on release profiles of 
sustained release matrix tablet of Acyclovir formulations. 
 To study the different types of Schemes on release profiles of sustained release matrix 
tablet of Acyclovir formulations. 
 To carry out Concurrent Process validation of the selected process of sustain release 
matrix tablet of Acyclovir  
 To perform stability studies as per ICH guidelines.
2.2     THE OBJECTIVES OF THIS STUDY 
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3. PLAN OF WORK 
                                      
 Literature survey. 
 Selection and procurement of suitable drug candidate and excipients. 
 Pre-formulation studies. 
 Characterization of drug 
• Melting point determination 
• Solubility determination 
• UV spectra (λ max) 
• IR spectra 
• Loss on drying 
• Standard carve of  Acyclovir 
• Percentage purity of drug 
 Identification and Drug polymer interaction study. 
 Fourier transform Infra-Red (FTIR) spectroscopy 
 Differential Scanning Calorimeter (DSC) 
    Physical Characterization of Powdered blend 
• Bulk density 
• Tapped density 
• Carr’s index 
• Hausner’s ratio 
• Angle of repose 
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  Formulation of  Sustained release matrix tablet of Acyclovir 
 Evaluation of  Sustained release matrix tablet  of Acyclovir 
• Appearance 
•  Dimensions ( Thickness and Diameter) 
• Hardness 
• Percent friability 
• Weight variation test 
• Drug content of Acyclovir (assay) 
• In-vitro dissolution studies 
• Kinetic of In-vitro Drug Release 
 Stability studies. 
 Result and discussion 
 Summary and conclusion   
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Basak S.C., et al., (2006): Monolithic matrix tablets of Ambroxol Hydrochloride 
were formulated as sustained release tablets employing Hydroxy Propyl Methyl Cellulose 
polymer, and the sustained release matrix tablets containing 75mg Ambroxol hydrochloride 
were developed using different drug polymer ratios of Hydroxy Propyl Methyl 
Cellulose.Tablets were prepared by direct compression.  Formulation was optimized on the 
basis of acceptable tablet properties and in vitro drug release. 
Chandria M., et al., (2009): The present investigation attempt has been madeincrease        
therapeutic efficacy, reduce frequency of administration  and improve patient Compliance, 
by developing sustained release matrix tablets of Zidovudine, were developed by using 
drug      polymer ration kollidon SR, HPMC k15M and HPMC K100M as matrix former 
lubricated formulation were compressed  by direct compression and wet granulation 
method.     Compressed tablets were evaluated for uniformity of weight, content of active 
ingredient,    friability, hardness, thinkess,  in-vitro dissolution, and swelling index, all 
formulation showed compliance with pharmacopeial standards. 
Ghosh S., et al., (2009): The objective of the study was to develop matrix tablets 
for oral controlled release of Aceclofenac. Matrix tablets of Aceclofenac, using various 
viscosity of hydrophilic polymer HPMC in two different proportions, hydrophobic polymer 
ethyl cellulose and Guar gum were prepared by wet granulation method and subjected to in 
vitro drug release studies. The drug release from all HPMC matrix tablets followed various 
release kinetics, formulation no - F7 followed Higuchi kinetics. Furthermore, the results of 
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the in vitro studies in pH 7.5 phosphate buffer medium showed that F7 tablets provided 
controlled release comparable with market sustained release formulation (Aeroff-SR 
tablets). 
Kabir A.K.L, et al., (2009): Objective of this study was to develop a sustained 
release matrix tablet of Acyclovir using hydroxypropyl methylcellulose (HPMC K15M and 
HPMC K100M CR in various proportions as release controlling factor by direct 
compression method. The results of dissolution studies indicated that the formulations F-2 
and F-3 could extend the drug release up to 24 hours. From this study, a decrease in release 
kinetics of the drug was observed when the polymer concentration was increased. Kinetic 
modeling of in vitro dissolution profiles revealed the drug release mechanism ranges from 
diffusion controlled or Fickian transport to anomalous type or non-Fickian transport, which 
was only dependent on the type and amount of polymer used. The drug release followed 
both diffusion and erosion mechanism in all cases. 
Saptarshi D., et al., (2010): An attempted was to formulate the oral sustained 
release    metformin hydrochloride matrix tablets by using hydroxyl methyl cellulose 
polymer (HPMC) as   
rate controlling factor and to evaluate drug release parameters as per various release kinetic   
models. It is observed that the basic goal of therapy in the development of metformin 
hydrochloride release dosage form is to increase bioavailability; reduce risk of 
hospitalization,    deliver drug at a near constant rate for approximately 12hrs; independent 
of food intact and  gastrointestinal pH. The dry granulation technique was used to compress 
the tablet as powder showed the poor flowability; wet granulation technique was not 
selected for the present work. 
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Soni T., et al., (2008): The development of a meaningful dissolution procedure for 
drug products with limited water solubility has been a challenge to the pharmaceutical 
industry. Aceclofenac (BCS Class II drug) is a non steroidal anti-inflammatory drug. There 
is no official dissolution medium available in the literature. In the present study, parameters 
such as solubility, medium pH, surfactant type, dissolution behavior of formulations, and 
influence of sink conditions, stability, and discriminatory effect of dissolution testing were 
studied for the selection of a proper dissolution medium. 
Yadav I.K. et al., (2010): The objective of the present study was to develop the 
oral sustained release matrix tablets of Aceclofenac using hydrophilic and hydrophobic 
polymers. Aceclofenac is a non steroidal anti-inflammatory agent used in symptomatic 
treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis and its 
biological half life is 4 hrs. Controlled release formulations of Aceclofenac (200 mg) were 
prepared by direct compression method. The drug release from optimized formulations F1, 
F4 and F7 was extended for a period of 12 hrs. The kinetic treatment to optimized 
formulations showed that the release of drug follows zero order model and Super Case II 
transport for F1 and F7. 
Yeole P.G., et al., (2006): In the present investigation, an attempt has been made to 
increase therapeutic efficacy, reduce frequency of administration, and improve patient 
compliance, by developing sustained release matrix tablets of Diclofenac sodium. 
Sustained release matrix tablets of Diclofenac sodium, were developed by using different 
drug:polymer ratios, such as F1(1:0:12), F2(1:0:16), F3(1:0:20), F4(1:0:24) and F5(1:0:28). 
Xanthan gum was used as matrix former, and microcrystalline cellulose as diluents. All the 
lubricated formulations were compressed using 8mm flat faced punches. 
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5.1. RAW MATERIAL USED 
Table.4: List of raw materials with source 
S. No Name of Ingredients Name of supplier 
1  
Acyclovir 
Ajanta pharmaceutical limited, 
Mumbai. 
2 Xanthan Gum Qualigens fine chemicals, Mumbai. 
3 Sodium Alginate Qualigens fine chemicals, Mumbai. 
4 Chitosan Paras Chem suppliers ,Pune, India. 
5 Polyvinyl Pyrolidone Qualigens fine chemicals, Mumbai 
6 Magnesium stearate Qualigens fine chemicals, Mumbai. 
7 Starch Qualigens fine chemicals, Mumbai. 
8 Talc Qualigens fine chemicals, Mumbai. 
9 Hydrochloric acid S d fine-chem limited, Mumbai. 
10 Chloroform Qualigens fine chemicals, Mumbai. 
11 Ethanol (95%) S d fine-chem limited, Mumbai. 
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5.2. EQUIPMENTS USED 
Table.5: List of equipments with model/make 
Sr. 
No Equipment Model/ Make 
1 Electronic balance Shimadzu BL-220H. 
2 Bulk density apparatus Indolab VTAP/MATIC-II. 
3 Standard sive (20 and 40#) Jayant scientific, IND. 
4 Hot air oven Chemi Equipments, Bombay. 
5 Sixteen punch tablet compression 
machine Cadmach, Ahemdabad, india. 
6 
Friability apparatus Veego scientific VFT-DV. 
7 Hardness tester Monsanto Hardness tester. 
8 Varnier caliper Indolab, MITUTOYO. 
9 Humidity chamber Labtech. 
10 USP tablet dissolution apparatus 
Type II Veego scientific VDA-8DR. 
11 
UV spectrophotometer Shimadzu-1700 PharmaspecUV-VISIBLE spectrophotometer. 
12 FTIR spectrophotometer Parkin elmer-Pharmaspec-1. 
13 
Differential scanning calorimeter Shimadzu DSC 60, Japan. 
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ACYCLOVIR:     (IP., 2007; Merck Index., 1997; USP., 2009; Tripathi K.D., 2004) 
 
Acyclovir is active against herpes group of virus; H. simplex type 1 is the most sensitive  
followed  by the H. simplex  type II> varicella-zoister  =Epstein-bar  virus; Cytomegalovirus 
(CMV) is practically not affected .the prototype antiviral agent used to treat various types of 
herpes infections. Since, acyclovir was the first antiviral to be considered  the gold  standard  for 
the  treatment  of herpes  infections,  all other  anti herpes virus medications  are compared  to 
it. It is approved  for the prophylaxis  of herpes genitals. 
A.  Chemical name: 
 
9 – [(2 hydroxyethoxy) methyl] -9H- guanine 2-amino-1, 9-dihydro-9-[(2- 
hydroxyethoxy) methyl]-6H-purin-6-one 
B.  Structural formula: 
 
 
 
O 
HN            N 
H2N       N       N 
 
 
CH 2OCH 2CH 2OH 
 
 
 Fig 6: Structure of Acyclovir 
 
5.3 DRUG PROFILE 
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C.  Physical properties: 
 
  Molecular formula    : C8H11N5O3 
 
 Molecular weight      : 225 
 
 Description                 : White, crystalline powder, fine powder 
 
 Odour                         : Characteristic 
 
 Taste                           : Bitter to alkaline 
 
 Melting point             : Melt at about 230º with decomposition (BP) 
 
  : Melt at about 250º with decomposition (USP) 
 
                Dissociation constant (pKa): 2.3, 9.2 
 
 Solubility                    : Freely soluble in dimethyl sulphoxide;  
                                        Slightly soluble in water;               
                               Very slightly in ethanol (95%); 
                                              Dissolves in dilute solutions of mineral acids and Alkaline                   
                                          hydroxides. 
               Storage                       : Store in well closed containers 
 
D.  Mode of action: 
 
Acyclovir is a synthetic analogue deoxy guanosine in which the carbohydrate moiety 
is acyclic.  The  modes  of action  of acyclovir  consist  of the following  consecutive 
mechanism: 
1.         Conversion to active acyclovir monophosphate within cells by viral thymidine 
kinase. This phosphorylation reaction occurs faster in infected cell than normal cell, because 
acyclovir is a poor substrate for the normal cell thymidine kinase. Acyclovir monophosphate  is 
further converted  in to di and triphosphate  by a normal cellular enzyme guanosine 
monophosphate kinase. 
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2.         Acyclovir  triphosphate  inhibits  viral DNA polymerase  by competing  deoxy 
guanosine triphosphate. The triphosphate drug is also incorporated in to viral DNA where it 
acts as a chain terminator,  because it has 3' - hydroxy  group, like cyclic sugar, 3' 5' - 
phosphodiester bond can be formed. It acts as suicide inhibitor because the terminated DNA 
template containing acyclovir as ligand binds irreversibly with DNA  polymerase  and  
inactivates.  It is a drug  of  choice  in  both  prophylaxis  and treatment of herpes simplex 
virus. 
Viral thymidine kinase 
Acyclovir                                                                   Active Acyclovir monophosphate 
 
Guanosine mono 
Phosphate kinase 
 
Acyclovir diphosphate 
 
Phosphate kinase 
 
 
 
Acyclovir triphosphate 
 
 
 
 
 
Deoxy guanosine                            DNA polymerase 
triphosate                                                                             DNA Chain terminates 
 
 
 
Fig. 7: Mechanism of Acyclovir 
 
 
E.  Pharmacokinetics: 
 
 Oral bioavailability                           : 15-30% 
 
 Protein binding                                  : 9-33% 
 
 Volume of distribution                      : 0.8 L/kg. 
 
                Half life                                               : 2.5-3.3 hours. 
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            Route of administration                    : Especially oral, IV, cream 5% 
 
                                                                              in an   aqueous cream base and eye ointment. 
F.  Absorption: 
 
Acyclovir  is poorly absorbed  from the gastro intestinal  tract following  oral 
administration.  The oral bioavailability  ranges from 10 to 20% and decreases with increased 
doses. The Cmax and AUC are dose dependent and show no proportionality. The Cmax  for a 
bioavailability  ranges from 10 to 20% and decreases with increased doses. The Cmax and 
AUC are dose dependent and show no proportionality. The Cmax for a 200 mg dose is 0.83 
µg/mL, 1.21 µg/mL for a dose of 400 mg and 1.61 µg/mL for a dose of 800 mg. Oral 
absorption is not affected by food consumption. There is minimal systemic absorption following 
topical administration of acyclovir. No drug is detectable in the blood or urine. Following 
intravenous administration  of acyclovir, the mean Cmax  is 9.8 µg/mL with a dose of 5 mg/kg 
every 8 hours and 20.7 µg/mL with a dose of 10 mg/kg every 8 hours. 
G.  Distribution: 
 
The volume of distribution  is 0.8 L/kg. Protein binding of acyclovir ranges from 9% 
to 33%, and distributes extensively throughout the body. The highest concentrations   are   in   
the   kidneys,   liver   and   intestines.   Cerebro   spinal   fluid concentrations are about 50% that 
of the plasma. Acyclovir does cross the placenta. 
H.  Metabolism: 
 
Acyclovir   is   converted   to   acyclovir   monophosphate   by   virus   specific 
thymidine kinase, diphosphate by cellular guanylate kinase, and then ultimately converted  to  
acyclovir  triphosphate   via  cellular  enzymes.  Acyclovir  undergoes minimal  hepatic  
metabolism   by  aldehyde  oxidase,  alcohol  dehydrogenase,   and aldehyde dehydrogenase to 
form inactive metabolites. 
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I.   Excretion: 
 
Acyclovir is primarily eliminated by the kidneys via glomerular filtration and tubular 
secretion. It is found in the urine from 62% to 90% as unchanged drug and metabolites.  The 
plasma  elimination  half life of Acyclovir  ranges from 2.5 to 3.3 hours in patients with 
normal renal function. 
J.   Contraindications: 
 
Hypersensitivity    to   valcyclovir,   acyclovir,   or   any   component   of   the 
formulations. 
K.  Precautions: 
 
Dosage  reduction  is  recommended  when  administering  acyclovir  to patients with 
renal impairment. 
o Use with caution in the elderly due to decreased renal function. 
 
o Use with caution in patients who receive nephrotoxic drugs. 
o  Use caution when  administering  via  IV  in  those  with  pre-existing        
neurologic abnormalities, serious hepatic or electrolyte abnormalities, or 
hypoxia. 
L.  Interactions: 
 Probenecid: concomitant administration of probenecid and Cimetidine with acyclovir  
increases  the acyclovir  mean  half life and under  the plasma   concentration   curve,   thus   
decreasing   renal   clearances   of probenecid. 
 
• Observe caution if administration nephrotoxic drugs simultaneous. 
• Zidovudine: Acyclovir along with zidovudine causes sever drowsiness 
and lethargy. 
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M. Dosage forms: 
 
• Intravenous infusion 
 
• Capsule 
 
• Tablet 
 
• Suspension 
 
• Topical cream 
 
• Topical ointment 
 
 
N.  Dosage limits: 
 
Capsules                                 : 200 mg 
 
Tablets                                    : 400 mg, 800 mg 
Suspension                              : 200 mg/5mL 
Powder for injection             : 500 mg, 1000 mg 
Solution for injection            : 50 mg/5mL 
Creams                                   : 5% 
Ointment                                : 5% 
 
 
O.  Over dosage Measures: 
 
Precipitation  of  acyclovir  in  renal  tubules  may  occur  when  the  solubility 
 (2.5 g/mL) is exceeded in the intra tubular fluid. This can be treated with hemo    
dialysis until renal function is restored. 
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P.  Commercial products of Acyclovir: 
 
Table 6: Commercial products of Acyclovir 
 
Trade name Dosage Form Recommended Dosage Manufacturer 
Acivir Tablet 
Injection 
Cream (5 %) 
Ointment (3 %) 
200, 400 and 800 mg 
 
10 mL 
 
5 g 
 
5 g 
Cipla 
Acivirall DT- tablet 200 and 400 mg Finecure 
Alovir Tablet 200, 400 and 800 mg Adley 
Axovir Tablet 
 
Injection 
200, 400 and 800 mg 
 
250 and 800 mg vials 
Samarth 
Clovirax DT- tablet 
 
Cream (5 %) 
200, 400 and 800 mg 
 
5 g 
Purehealth 
Cyclovir Tablet 
 
Cream (5 %) 
200 mg 
 
5 g 
Zydus cadilla 
Herpex DT- tablet 
 
Cream (5 %) 
200 and 800 mg 
 
5 g 
Torrent 
Lovir Tablet 400 and 800 mg Eli lilly 
Ocuvir Ointment (3 % ) 5 g FDC 
Zovirax Suspension 
Ointment (3 %) 
Tablet 
400 mg/5 Ml 
 
5 g 
 
200, 400 and 800 mg 
GSK 
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A)  XANTHAN GUM                                                     (Rowe R.C., et.al., 2003) 
Synonyms               :          Corn sugar gum; E415; Xantural; Rhodigel. 
Chemical name          : Xanthan gum. 
Molecular Weight     :  2000000. 
Description                :  Cream or white-colored odorless free flowing fine  
powder. 
Structural formula : 
  
 
     Figure.8 Structure of Xanthan gum 
Solubility           : Practically insoluble in ethanol and ether.  
           Soluble in cold or warm water.  
Viscosity                     :       The viscosity of xanthan gum solution is considerably  
increased or gelation occurs, in the presence of some 
materials such as ceratonia, guar gum and magnesium 
aluminium silicate. 
Incompatibilities     : Xanthan gum is an anionic material and is not usually  
compatible with cationic surfactants as precipitation occurs. Xanthan gum is compatible 
with most synthetic and natural viscosity increasing agents. 
 
5.4. POLYMER PROFILE 
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Functional Category     :   Viscosity increasing agent, suspending agent. 
Applications in pharmaceutical formulation: 
Xanthan gum is widely used in oral and topical pharmaceutical formulations. It is 
used as   Viscosity increasing agent, suspending agent, and also has been used to prepare 
sustained release matrix tablets. 
Stability and storage conditions: 
It is a stable material. The bulk material should be stored in a well closed container 
in a cool, dry place.   
 
B)  SODIUM ALGINATE                                         ( Row R.C.,et al., 2003) 
Nonproprietary Names: 
 BP: Sodium alginate,  PhEur: Natrii alginas, USPNF: Sodium alginate 
Synonyms: 
  Algin; alginic acid, sodium salt; E401; Kelcosol; Keltone; Protanal; sodium 
 polymannuronate. 
Chemical Name and CAS Registry Number: Sodium alginate [9005-38-3] 
Empirical Formula : (C
6
H
7
O
6
Na) n 
Molecular Weight: The block structure and molecular weight of sodium alginate   
                                 samples has  been investigated. 
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 Structural Formula: 
                         
                           Figure 9: Structure of Sodium Alginate 
Functional Category: 
   Stabilizing agent; suspending agent; tablet and capsule disintegrant; tablet 
binder;  viscosity-increasing agent. 
   Grades:  
   Various grades of sodium alginate are available yielding aqueous solutions 
of  varying viscosities within a range of 20 to 400 centipoises in 1% solution at 20
º
C. 
 Applications in Pharmaceutical Formulation or Technology: 
o Sodium alginate for oral and topical pharmaceutical formulations. 
o  In tablet formulations, sodium alginate may be used as both a binder and 
disintegrant, diluents in capsule formulations. Sustained release oral formulations are 
prepared by using, since it can delay the dissolution of a drug from tablets, capsules and 
aqueous suspensions. In topical formulations, sodium alginate is mainly used as a 
thickening and suspending agent in product such as variety of pastes, creams, and gels, 
and as a stabilizing agent for oil-in-water emulsions  
o  Recently, sodium alginate has been used mostly for microencapsulation of drugs, in 
contrast with the more conventional microencapsulation techniques which use organic 
solvent systems. It has also been used in the formulation of nanoparticles. Other NDDS 
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containing sodium alginate include ophthalmic solutions that form a gel in situ when 
administered to the eye. 
Description: 
  Sodium alginate occurs naturally as an odorless and tasteless, white to pale   
yellowish-brown colored powder. 
Typical Properties: 
 Acidity/alkalinity: pH 7.2 for a 1% w/v aqueous solution 
Solubility:  
        Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water 
mixtures in which the ethanol content is greater than 30%. Also, the pH is less than 3. 
Slowly soluble in water, forming a viscous colloidal solution. 
Stability and Storage Conditions: 
  Sodium alginate is a hygroscopic material, although it is stable if stored at 
low relative humanities and a cool temperature. 
 
C) CHITOSAN                                                                      (Rowe R.C., et al., 2003) 
Synonyms                    :   2-Amino-2-deoxy-(1, 4)-β-D-glucopyranan,  
deacetylated chitin,  deacetylchitin. 
Chemical Name          :  Poly-β-(1,4)-2-Amino-2-deoxy-D-glucose. 
 Molecular Weight     :  Chitosan is commercially available in several types and 
grades that vary in molecular weight between 10,000 and 10, 00,000 and vary in degree of 
deacetylation and viscosity. 
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 Structure                      :                             
 
 
 
Figure.11 Structure of Chitosan 
Description            :      Chitosan occurs as odorless, white or creamy-powder or  
flakes. Fibre formation is quite common during precipitation 
and the chitosan may look cottonlike. 
Functional Category   :  Coating agent, film-forming agent, Mucoadhesive tablet  
binder and viscosity-increasing agent. 
Acidity/Alkalinity         : pH = 4.0–6.0 (1% w/v aqueous solution) 
Density                           : 1.35–1.40 g/cm3 
Glass Transition Temperature:    203°C. 
Solubility                      : It is sparingly soluble in water, practically insoluble in 
ethanol,    
organic solvents, and neutral or alkali solutions. Chitosan 
dissolves readily in dilute and concentrated solutions of most 
organic acids. The solubility is affected by the degree of 
deacetylation. 
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Viscosity (dynamic)  : A wide range of viscosity types is commercially available.  
Chitosan is an excellent viscosity- enhancing agent in an 
acidic environment. 
Applications    :  It is used as a component of sustained release dosage  
form & mucoadhesive dosage forms. 
Stability and Storage:  Chitosan powder is a stable material at room  
temperature, although it is hygroscopic after drying. Chitosan 
should be stored in a tightly closed container in a cool, dry 
place.  
Incompatibilities   :  Chitosan is a cationic material. Chitosan is incompatible  
with strong oxidizing agents.  
 
 
 
1) STARCH                                                                      (Rowe R.C., et.al., 2003) 
Non-Proprietary name :           Maize starch, Potato starch. 
Synonym   :           Amido, Amilo 
Incompatibilities  :           With some drugs which form a complex  
(complexation reaction) and retain in kidneys as 
oxalate complexes. 
5.5. EXCEPIENTS PROFILE 
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Chemical Name and CAS Registry Number: Starch [9005-25-8] 
Chemical Formula  :            [C6H10O5] where n= 300-1000. 
Category   : Glidant, capsule diluents, capsule disintegrant,  
tablet binder. 
Description   :         White to off-white powder comprising very  
small spherical or ovoid granules. 
Solubility   : Insoluble in cold water and cold ethanol 
Stability   : Dry, unheated starch is stable if protected from  
high humidity 
Storage   :          To be stored in a well closed container, cool and  
dry place. 
Safety    : Allergic reactions to starch are very rare and 
individual apparently allergic to one particular starch may not experience  adverse effects 
with a starch from a different botanical sources. 
Particle size   : Corn starch: 2-32 µm; Potato starch: 10-100 µm;  
Rice starch: 2-20 µm; Wheat starch: 2-45 µm. 
Viscosity   :          13.0 cP for a 2%w/w aqueous dispersion of corn  
Starch at 25 °C 
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2)
 TALC        
(Rowe R.C., et.al., 2003) 
Synonyms   : French chalk, purified talc, talcum, soapstone 
Description   : A very fine, white to grayish white, impalpable,  
odorless crystalline powder, unctuous, adheres readily 
to skin, soft to touch and free from granules. 
Empirical formula  : Mg.6 (Si2O5) 4(OH)4 
Functional category  : USP: Tablet and/or capsule lubricant, Glidant  
and anti caking agent 
                   BP:   Talc dusting powder 
                    Others: Anti adherent 
Typical Properties: 
Density   : 19-24 Ib/ft 
Solubility   : Insoluble in water, organic solvents, cold acids  
and dilute alkalis 
Stability and storage conditions:     Stable, Preserve in a well-closed container 
Incompatibilities  : Quaternary ammonium compounds 
Safety    : Talc dust exposure in the modern mining  
     process does not appear to be injurious to health.  
     Contamination of tissues with talc is liable to  
     cause granulomas. Talc should not be inhaled.  
     Being unreactive, talc may be considered  
     practically non-toxic on ingestion. 
 
ACYCLOVIR SUSTAINED RELEASE MATRIX TABLET     MATERIALS AND EQUIPMENTS 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 56 
 
3)  MAGNESIUM STEARATE                                      (Rowe R.C., et.al., 2003) 
Synonyms   : Metallic stearate, Magnesium salt 
Functional Category  : USP: Tablet and/or capsule lubricant 
             BP/EP: Lubricant; Pharmaceutical  
             Other: Glidant, Anti-adherent 
Empirical Formula  : C36H70MgO4 
Molecular Weight  : 591.3 
Structure   : 
                                         CH3 (CH2)16 COO                           
                                                                                        Mg  
                                         CH3 (CH2)16 COO 
Description   : It is a fine, white, precipitated or milled,  
impalpable powder of low bulk density. Odour and 
taste are slight but characteristic. The powder readily 
adheres to the skin.                                                                                                         
Typical Properties  : 
 Solubility   : Insoluble in water, alcohol and ether. Slightly  
soluble in hot alcohol and benzene.   
 
Stability and storage conditions: Stable, non-self-polymerizable. Store in a well  
closed container.                                   
Incompatibilities  : Acidic substances; alkaline substance; iron salts.  
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Avoid mixing with strong oxidizing materials. Use 
with caution with drugs, which are incompatible with 
alkali.  
Safety    :  It is described as an inert or nuisance dust. It is  
classified as non-hazardous by the department of 
transportation regulations.  
4) POLYVINYL PYROLIDONE (PVP) 
Nonproprietary Names :  None adopted. 
Synonym   :  Aminobutyric acid lactam; 4-aminobutyric acid  
lactam; aminobutyric lactam; minobutyrolactam; 
butyrolactam; butyrolactam; 2-oxopyrrolidine; 2-
Pyrol; apyrrolidinone; pyrrolidone;  a-pyrrolidone; 
Soluphor P. 
Chemical Name          :  2-Pyrrolidinone 
CAS Registry Number       :  [616-45-5] 
Empirical Formula            :  C4H7NO 
Molecular Weight          :  85.11 
Description            :  2-Pyrrolidone occurs as a colorless or slightly  
colored liquid that solidifies at room temperature and 
has a characteristic odor. 
Functional Category          :  Penetration enhancer; plasticizer; solvent;  
solubilizing agent. 
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Applications in Pharmaceutical Formulation or Technology:  
Pyrrolidones such as 2-pyrrolidone and N-methylpyrrolidone are mainly used as 
solvents in veterinary injections.1, 2 they have also been suggested for use in human 
pharmaceutical formulations as solvents in parenteral, oral, and topical applications. In 
topical applications, pyrrolidones appear to be effective penetration enhancers.1–7 
Pyrrolidones have also been investigated for their application in controlled-release depot 
formulations. Poly-vinyl Pyrrolidone is used in the formulation as plasticizer. 
  
 
 
EXPERIMENTAL        
        WORK
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 6.1 PREFORMULATION STUDIES 
Before the formulation of a product should be investigation of physical and chemical  
properties  of a drug substance  alone to effective,  stable and safe dosage form. It is the first 
step in rational development of dosage form. 
6.1. Identification of Drug: 
 
The preliminary studies were carried out by testing of different physical and chemical 
properties of drug as follows. 
6.1.1. Organoleptic Properties of Drug:                                       (Lachman L., 1991) 
 
The Organoleptic properties like physical state, color, taste, odor etc., of the drug 
was reported with help of the descriptive terminology. It helps to identify the drug. 
6.1.2. Melting Point:                                                                                       (IP., 2007) 
 
It is the easy way to identify the drug. The melting point of acyclovir was tested 
by use of a laboratory  melting point apparatus with capillary tube method a procedure given 
in the Indian Pharmacopeia 2007. 
6.1.3. Solubility Profile:                                                                                  (IP., 2007) 
 
It is important  to know about solubility  characteristic  of a drug in aqueous system, 
since they must possess some limited aqueous solubility to elicit a therapeutic response.   The   
solubility   of   drug   was   recorded   by   using   various   descriptive terminology specified in 
Indian pharmacopoeia, 2007. 
6. EXPERIMENTAL WORK 
ACYCLOVIR SUSTAINED RELEASE MATRIX TABLETS       EXPERIMENTAL WORK 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 60 
 
Table 7: Description of solubility 
 
Descriptive term Parts of solvent required for 1 part of solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble Greater than or equal to 10,000 
 
 
6.1.4. UV Spectroscopy (λ max):                                               (Kuchekar B. S., 2006) 
 
The  absorption  maximum  of  the  standard  solution  was  scanned  between 
 
200- 400 nm regions on Shimadzu-1700 Pharmaspec UV-visible spectrophotometer. The 
absorption maximum obtained with the substance being examined corresponds in position and 
relative intensity to those in the reference spectrum. 
6.1.4.1. Development of Standard Curve of Acyclovir in Distilled Water: 
 
(Kuchekar B. S., 2006) 
 
Preparation of Stock Solution of Acyclovir in Distilled Water: 
 
Weighed accurately about 200 mg of Acyclovir was dissolved in little quantity of  
distilled  water  and  volume  was  adjusted  to  100  ml  with  the  same  to  prepare standard 
solution having concentration of 1000 µg/ml. From this solution, pipette out 10 ml and made 
up to 100 ml with distilled water to produce 100 µg/ml. 
Procedure: 
 
From  the  stock  solution,  aliquots  of  0.4,  0.8,  1.2,  1.6  and  2  ml  were transferred  
to 10 ml volumetric  flasks  and final volume  was made to 10 ml with 
distilled  water  to  get  4  to  20  µg/ml.  Absorbance  values  of  these  solutions  were measured  
against  blank  (Distilled  water)  at  252  nm  using  UV-visible spectrophotometer. 
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6.1.4.2. Development of  Standard Curve of Acyclovir in 0.1N HCl:  
       Preparation of   0.1N HCl: 
0.1N HCl was prepared according to I.P. 1996. Accurately 8.5 ml of HCl was taken 
and diluted with freshly prepared distilled water to produce 1000 ml.  
Preparation of Stock Solution of Acyclovir in 0.1N HCl: 
Weighed accurately about 200 mg of Acyclovir was dissolved in little quantity of 0.1N 
HCl and volume was adjusted to 100 ml with the same to prepare standard solution having 
concentration  of 1000 µg/ml. From this solution, pipette out 10 ml and made up to 100 ml 
with 0.1N HCl to produce 100 µg/ml. 
Procedure: 
 
From the stock solution, aliquots of 0.4, 0.8, 1.2, 1.6 and 2 ml were transferred to 10 ml 
volumetric flasks and final volume was made to 10 ml with 0.1N HCl to get 4 to 20 µg/ ml. 
Absorbance values of these solutions were measured against blank (0.1N HCl) at 255 nm 
using UV-visible spectrophotometer. 
6.1.4.3. Development of  Standard Curve of Acyclovir in phosphate buffer  pH
 
 7.4: 
      Preparation  of   phosphate buffer  pH
 
 7.4: 
Phosphate buffer  pH
 
 7.4 was prepared according to I.P. 1996. Accurately 8.5 ml of  
phosphate buffer  pH
 
 7.4 was taken and diluted with freshly prepared distilled water to produce 
1000 ml.  
Preparation of Stock Solution of Acyclovir in phosphate buffer  pH
 
 7.4: 
Weighed accurately about 200 mg of Acyclovir was dissolved in little quantity of 
phosphate buffer  pH
 
 7.4  and volume was adjusted to 100 ml with the same to prepare 
standard solution having concentration  of 1000 µg/ml. From this solution, pipette out 10 ml 
and made up to 100 ml with phosphate buffer  pH
 
 7.4 to produce 100 µg/ml. 
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Procedure: 
 
From the stock solution, aliquots of 0.4, 0.8, 1.2, 1.6 and 2 ml were transferred to 10 ml 
volumetric flasks and final volume was made to 10 ml with phosphate buffer  pH
 
 7.4 to get 
4 to 20 µg/ ml. Absorbance values of these solutions were measured against blank 
 
phosphate buffer  pH
 
 7.4  at 275 nm using UV-visible 
spectrophotometer. 
 
B.  Compatibility testing of drug with polymer (IP, 2007; Aulton M.E., 2002; Silverstein 
R.M, Webster F.X., 2003; Skoog D.A.,et.al.,1996) 
 The proper design and formulation of a dosage form requires consideration of the 
physical, chemical and biological characteristics of all drug substances and excipients to be 
used in the fabricating the product. Each polymer used in the formulations was blended 
with the drug levels that are realistic with respect to the final dosage form. Each polymer 
was thoroughly blended with drug to increase drug - polymer molecular contacts to 
accelerate the reactions if possible. 
 
 
Figure.12: Schematic representation of compatibility studies 
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A. Fourier Transforms Infra-Red (FTIR) spectroscopy  
   FTIR study was carried out to check compatibility of drug with polymers. 
Infrared spectrum of Acyclovir was determined on Fourier transform Infrared 
Spectrophotometer using KBr dispersion method. The base line correction was done using 
dried potassium bromide. Then the spectrum of dried mixture of drug and potassium 
bromide was run followed by drug with various polymers by using Parkin elmer-
Pharmaspec-1 FTIR spectrophotometer. The absorption maximums in spectrum obtained 
with the substance being examined correspond in position and relative intensity to those in 
the reference spectrum represented in Table 20 and 22, Also  Figure 19 to 22 respectively.  
 
B. Preparation and evaluation of Powdered blend (Lachman L, et al., 1991; Bankar G.S. 
and Rhodes C.T.,2009; Kabir., et al., 2009; Ghosh S and Barik B., 2009; Umash D., et al., 
2009) 
Table 8: Composition of Acyclovir Sustained Release Matrix tablets for formulations 
    
Ingredients (mg/ml/tab) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Acyclovir 200 200 200 200 200 200 200 200 200 
Xanthan gum 35 70 105 - - - - - - 
Sodium Alginate - - - 35 70 105 - - - 
Chitosan - - - - - - 35 70 105 
Starch 79 44 09 79 44 09 79 44 09 
Polyvinyl Pyrolidone 20 20 20 20 20 20 20 20 20 
Talc 10 10 10 10 10 10 10 10 10 
Magnesium Stearate 6 6 6 6 6 6 6 6 6 
Total weight 350 350 350 350 350 350 350 350 350 
A, Angle of repose  
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  The frictional force in the powder can be measured by the angle of repose. 
  Angle of repose is calculated by fixed funnel method. In this method, funnel was 
fixed to a stand so that the lower tip of the funnel was 2.5 cm above the surface; a graph 
paper was placed o.kn a flat surface. The blend was allowed to fall freely on the graph 
paper through the funnel, till the tip of the heap formed just touches the funnel. The radius 
of the heap was noted and from this angle of repose was determined. 
  Angle of repose θ can be calculated the equation as follows: 
Tan θ = h/r 
    Where,  h = height of the heap in cm. 
       r = radius of the heap in cm. 
 
Table 9: Relationship between Angle of Repose (θ) and Flowability 
Angle of Repose (θ) Flowability 
< 20 Excellent 
20-30 Good 
30-34 Acceptable 
> 40 Very poor 
 
a, Bulk Density 
  For the determination of bulk density a sample of about 2g was poured into a 10 ml 
graduated cylinder. The cylinder was dropped at 2 seconds interval into a hard wooden 
surface three times from a height of 2.5 cm. 
    The volume was recorded and the bulk density was calculated using the formula. 
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Bulk density  = weight of blend /bulk volume of blend 
The results are summarized in the table no.24.  
 
b, Tapped Density 
  A sample of about 2g was poured gently into a 10 ml graduated cylinder. The 
cylinder was dropped at 2 seconds interval from a height of 2.5cm. The tapped density was 
calculated by measuring final volume after 100 taps on a wooden surface. 
Tap density  =  weight of blends/ tapped volume of blends 
 
c, Compressibility Index 
  The packing ability of the granules was evaluated from the change in volume, 
which is due to rearrangement and packing occurring during tapping. It is expressed as 
Carr’s Compressibility Index (CC %) and is calculated as follows. 
 
100x
TD
)BDTD(CI −=
 
                    Where,  TD – Tap density 
    BD – Bulk density 
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Table 10: Relationship between CC% and Flowability 
                                   
CC % 
Flowability 
5-15 Excellent 
12-16 Good 
18-21 Fairly acceptable 
23-35 Poor 
33-38 Very poor 
< 40 Very very poor 
 
a. Hausner’s Ratio 
Hausner’s ratio was determined by following equation,    
 
A hausner ratio less than 1.25 indicates good flow while greater than 1.5 indicates poor 
flow. 
 
6.2. Formulation of Sustained release matrix tablet of Acyclovir  
(Lachman L., et al., 1991; Bankar G.S., and Rhodes C.T., 2009; Yadav I.K., et al., 2010) 
 The tablet was prepared by simple blending of active ingredient with polymers, 
filler, binder, lubricant and flow promoter followed by direct compression method (Table 
5). 50 tablets were prepared for each proposed formulation. Properly weighed Xanthan 
gum, Sodium Alginate and Chitosan, magnesium stearate, and the active ingredient were 
then taken in a photo film container and blended in 16 stations Cadmach tablet 
compression machine and compressed with 10mm flat faced punches by using direct 
compression technique. Compression force was kept constant for all formulations. The 
main steps in direct compression methods are, 
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1. Sieving 
 Acyclovir was passed through sieve # 40. 
 Polymers, magnesium stearate were passed through sieve #40. 
 Xanthan gum, Sodium Alginate and Chitosan, polymers are taken with drug  
in the different ratios  
2. Dry mixing 
 The above sieved materials were mixed thoroughly by tumbling method in a 
polythene bag.  
3. Lubrication 
 The powders were lubricated with Magnesium stearate. 
4. Compression 
 The lubricated powders were compressed using beveled flat faced punches 
of 10mm diameter. 
 Parameters like average weight, hardness, and friability are checked during 
compression as in process quality measures. 
  The main steps in direct compression methods were 
 Blending of drug and polymers 
 ↓ 
 Passing through sieve  
 ↓ 
 Lubrication of blend 
 ↓ 
 Compression of lubricated powders 
 
 
 
 
ACYCLOVIR SUSTAINED RELEASE MATRIX TABLETS       EXPERIMENTAL WORK 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 68 
 
 6.3. Evaluation of Sustained release matrix tablet of Acyclovir     (IP, 2007;               
Lachman L, et al., 1991; Bankar G.S. and Rhodes C.T., 2009) 
a) Thickness 
  The thickness of the tablets was determined using a vernier caliper. Five tablets 
from each formulation were evaluated and average values were calculated. 
b) Weight variation test         (IP, 2007) 
  For weight variation, 20 tablets of each type of formulation were weighed 
individually on an electronic balance, average weight was calculated and individual tablet 
weight was then compared with the average value to find out the deviation in weight. 
Table 11: Specifications of %Weight variation allowed in tablets as per IP. 
Sr. No Average Weight of tablet % Deviation 
1. 80 mg or less 10 
2 More than 80 but less than 250 mg 7.5 
3 250 mg or more 5 
 
c) Hardness For each type of formulation, the hardness value of 6 tablets was 
determined using Monsanto hardness tester.  
d) Friability 
  Friability of Acyclovir tablets was tested using a friabilator (Friability testing 
apparatus, Electro lab, Mumbai.) A loss of less than 1% in weight was acceptable. The 
weight of 10 tablets was noted initially (W1) and placed in the friabilator for 4 min /100 
rpm. The tablets were reweighed and noted as (W2). The difference in the weight is noted 
and expressed as percentage.  
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          The percent friability was determined using the formula: 
Percentage friability =
1W
2W1W −
  X 100 
         Where,   W1=Tablets was noted initially 
W2= tablets were reweighed and noted as 
Limits for Friability are usually less than 1%.                                     
e) Content uniformity         (IP., 2007) 
  Content uniformity was determined by accurately weighing 5 tablets and crushing 
them in mortar with the help of a pestle. Then an accurately weighed quantity of powder 
equivalent to 50 mg of drug was transferred to a 50 ml volumetric flask. 50 ml of Methanol 
was added and shaken. Volume was made upto 50 ml with Methanol. The solution was 
filtered through whatman filter paper. First few ml of the filtrate was discarded. 1 ml of the 
filtrate was diluted to 25 ml with Methanol. Then   3 ml of the resulting solution was again 
diluted to 10 ml with Methanol. The absorbance of the resulting 10 µg/ml solution was 
recorded at 275nm. 
 
Content uniformity was calculated using formula 
% Purity = 10 C (Au / As) 
 Where, C = concentration, Au and as are absorbance obtained from standard preparation 
and assay preparations respectively. 
f) In-vitro dissolution studies (IP., 2007; Dressman J and Krammer J., 2005; Soni 
T.,  et al., 2008; Yeole P.G., et al., 2006) 
The in vitro dissolution studies were performed using USP-22 type I dissolution 
apparatus at 50rpm. Dissolution test was carried out upto 11 hours using 0.1N HCl (PH 1.2) 
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solution (900 ml) as dissolution medium at 37 ± 0.5°c for first 2 hours, and PH 7.4 
phosphate buffer solution (900 ml) for the rest of the period. An aliquot (5ml) was 
withdrawn at specific time intervals and drug content was determined by U.V. 
spectrophotometer (Schimadzu, 1601) at 255.55 nm for PH 1.2 and 275 nm in PH 7.4. It was 
made clear that none of the ingredients used in the matrix formulations interfered with the 
assay. The release studies were conducted in triplicate. 
g) Data Analysis (Curve Fitting Analysis) ( Brahmankar D.M and Jaiswal S.B., 
2005; Chandira., et al., 2009) 
  To analyze the mechanism of the drug release rate kinetics of the dosage form, the 
data obtained were graphed as: 
i. Cumulative percentage drug released Vs Time (In-vitro drug release plots) 
ii. Cumulative percentage drug released Vs Square root of time (Higuchi’s plots) 
iii. Log cumulative percentage drug remaining Vs Time (First order plots) 
iv. Log percentage drug released Vs Log time (Peppas plots) 
 
 
Higuchi release model 
 To study the Higuchi release kinetics, the release rate data was fitted to the 
following equation.    F = K.t ½ 
   Where,  ‘F’ is the amount of drug release, 
     ‘K’ is the release rate constant, and      ‘t’ is the release time. 
  When the data is plotted as accumulative drug released versus square root of time, 
yields a straight line, indicating that the drug was released by diffusion mechanism. The 
slope is equal to ‘K’. 
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Korsmeyer and Peppas release model 
  The release rate data were fitted to the following equation, 
Mt / M∞   = K. tn 
  Where,   Mt / M∞ is the fraction of drug release,  
      ‘K’ is the release constant, 
      ‘t’ is the release time, 
  ‘n’ is the diffusional exponent for the drug release that dependent on the shape of 
the matrix dosage form. 
  When the data is plotted as Log of released versus Log time, yields as straight line 
with a slope equal to ‘n’ and the ‘K’ can be obtained from Y – intercept. 
  For non- Fickian release the ‘n’ values falls between 0.5 and 1.0 while for Fickian 
 (case I) diffusion n= 0.5 and zero order release ( case II transport) n= 1.0. 
Zero order release rate kinetics 
  To study the zero-order release kinetics the release rate date are fitted to the 
following equation. 
F = Kt 
     Where ‘F’ is the fraction of drug release, 
      ‘K’ is the release rate constant and  
      ‘t’ is the release time. 
  When the data is plotted as cumulative percent drug release versus time, if the plot 
is linear then the date obeys zero-order release kinetics, with a slope equal to K.  
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6.4. Stability studies (Manavalan R., 2004; Yadav I.K., et al., 2010) 
  Tablets were placed in tightly screwed bottles. The bottles were then kept in a 
stability chamber, which was maintained at 400 c and 75% RH. 
  The samples were withdrawn after 30 days and all the tests like hardness, friability, 
content uniformity and in vitro dissolution were carried out. 
  The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling recommended 
storage conditions, re-test periods and shelf-lives. Generally, the observation of the rate at 
which the product degrades under normal room temperature requires a long time. To avoid 
this undesirable delay, the principles of accelerated stability studies are adopted. The 
International Conference on Harmonization (ICH) Guidelines titled “Stability testing of 
New Drug Substances and Products describes the stability test requirements for drug 
registration application in the European Union, Japan and the States of America. 
 
ICH specifies the length of study and storage conditions; 
   Long-Term Testing: 25
0 
C ± 2
0 
C at 60% RH ± 5% for 12 Months  
  Accelerated Testing: 40
0 
C ± 2
0 
C at 75% RH ± 5% for 6 Months  
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Method:  
The selected formulations were packed in amber-colored bottles, which were tightly 
plugged with cotton and capped. They were then stored at 250 C at 60% and 400 C at 75 % 
RH for 3 months and evaluated for their physical appearance, drug content and drug 
excipients compatibility at specified intervals of times. 
 
 
 
 
 
 
 
 
  
 
RESULTS  
AND  
DISCUSSION 
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7.1. Preformulation parameters: 
 
7.1.1. Organoleptic Properties                                             (Lachman L., 1991) 
 
Physical state  :  Fine powder 
 
Colour             :  A white fine powder 
 
Odour              :  Characteristic 
 
Taste               :   Bitter to alkaline 
 
7.1.2. Melting Point:                                                                          (IP., 2007) 
 
Melting   point   of   Acyclovir   was   found   to   be   256.6   ±1.150C   
with decomposition. The official melting point range for Acyclovir is between 
256-258°C. Hence, results were complied the limits specified in official Book. 
7.1.3. Solubility Profile: 
 
Table 12: Solubility of Acyclovir in various solvents 
 
 
 
Name of solvent 
 
Solubility 
Dilute HCl Soluble 
Water Slightly soluble 
Alcohol Sparingly soluble 
Acetone Insoluble 
 
The results were complied with official solubility of Acyclovir (IP 2007) 
 
 
 
 
7. RESULTS AND DISCUSSION 
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7.1.4. UV Spectroscopy (λ max): 
 
7.1.4.1. Determination of λ max for Acyclovir by using Distilled Water: 
 
The absorption maximum for Acyclovir in Distilled Water was found to be 
252 nm and it is shown in Figure 13. 
 
 
 
Figure. 13: λ max Observed for Acyclovir in Distilled Water 
 
7.1.4.2. Preparation of Standard Curve for Acyclovir by using Distilled     
          Water: 
 
UV absorption spectrum of Acyclovir in Distilled Water showed λ max  at 252 
 
nm. Absorbance obtained for various concentrations  of Acyclovir in distilled water 
 
was given in Table 13. The graph of absorbance Vs. concentration for Acyclovir was 
 
found  to  be linear  in  the  concentration  range of  4  -  20 μg/ml.  The  drug  obeys 
 
Beer - Lambert’s law in the range of 4 - 20 μg/ml which was shown in Figure 14. The 
 
calibration parameters were shown in Table 14. 
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Table 13: Data of concentration Vs absorbance for Acyclovir in  
                  Distilled Water 
 
 
S. No. 
Concentration 
 
(µg/ml) 
 
Absorbance at 
252nm 
1. 0 0 
2. 4 0.191 
3. 8 0.375 
4. 12 0.563 
5. 16 0.744 
6. 20 0.931 
   
 
 
Table 14: Data of calibration curve parameter in Distilled Water 
 
S. No. Parameters Values 
 
1. 
Correlation 
Coefficient (r) 
 
0.9999 
2. Slope (m) 0.04644 
3. Intercept (c) 0.00290 
ACYCLOVIR SUSTAINED RELEASE MATRIX TABLETS       RESULTS AND DISCUSSION 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 77 
 
 
Ab
so
rb
an
ce
 
at
 
25
2 
n
m
 
 
 
 
1.4 
 
1.2 
 
1 
 
0.8 
 
0.6 
 
0.4 
 
0.2 
 
                                 0                  5                10                5                  20               25 
Concentration( µg/ml) 
 
 
Figure 14: Standard graph for Acyclovir in Distilled Water 
 
7.1.4.3. Determination of λ max for Acyclovir by using 0.1N HCl: 
The absorption maximum for Acyclovir by using 0.1N HCl was found to 
be 255.55 nm and it is shown in Figure 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15: λ max Observed for Acyclovir in 0.1N HCl 
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7.1.4.4. Preparation of Standard Curve for Acyclovir by using 0.1N HCl: 
 
The UV absorption spectrum of Acyclovir in 0.1N HCl shown λ max at 
255.5nm. Absorbance obtained for various concentrations of Acyclovir in 0.1N 
HCl were given in Table 15. The graph of absorbance Vs. concentration for 
Acyclovir was found to be linear in the concentration range of 4 - 20μg /ml. The 
drug obeys Beer - Lambert’s law in the range of 4 - 20μg /ml which was shown in 
Figure 16.  The calibration parameters were shown in Table 16. 
Table 15: Data of concentration Vs absorbance for Acyclovir in 0.1N HCl 
 
 
S. No. 
Concentration 
 
(µg/ml) 
 
Absorbance at 
 255.5 nm 
1. 0 0.000 
2. 4 0.235 
3. 8 0.455 
4. 12 0.683 
5. 16 0.914 
6. 20 1.143 
 
 
 
 
Table 16: Data for calibration curve parameters in 0.1N HCl 
 
S. No. Parameters Values 
1. Correlation Coefficient (r) 0.9999 
2. Slope (m) 0.057 
3. Intercept (c) 0.0016 
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Fig. 16: Standard graph of Acyclovir in 0.1N HCl 
 
 
 
 
7.1.4.5. Determination of λ max for Acyclovir by using Phosphate buffer P
H
 7.4: 
[ 
  The absorption maximum for Acyclovir was found to be 275 nm and it is 
shown in Figure 17. 
 
 
 
Figure.17 λ max observed for Acyclovir in Phosphate buffer PH 7.4 
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7.1.4.6. Preparation of Standard Curve for Acyclovir By using in Phosphate buffer 
            PH 7.4: 
            UV absorption spectrum of Acyclovir in Phosphate buffer PH 7.4 showed λ max at 275 
nm. Absorbance obtained from various concentrations of Acyclovir Phosphate buffer PH 7.4 
were given in table 17. The graph of absorbance Vs concentration for Acyclovir was found to be 
linear in the concentration range of 4 – 20 μg/ml. The drug obeys Beer-Lambert’s law in the 
range of 5 – 30 μg /ml. 
 
Table 17: Data of Concentration Vs absorbance for Acyclovir in Phosphate buffer PH 7.4 
                
 
 
 
Table 18:  Data of Calibration Curve Parameter in Phosphate buffer PH 7.4 
Sr. No. Parameters  Values  
1 Correlation coefficient (r) 0.9991 
2 Slope (m)             40.10 
3 Intercept(c) 0.206 
 
Sr. No. Concentration (µg/ml) Absorbance(nm) 
1 0 0.0000 
2 4 0.110 
3 8 0.209 
4 12 0.327 
5 16 0.414 
6 20 0.484 
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         Figure 18: Standard graph of Acyclovir in Phosphate buffer PH 7.4  
       
7.1.5. Quantification of Drug: 
 
The percentage purity of drug was calculated by using calibration graph 
method (least square method) and the data has been shown in Table 19. 
Table 19: Percentage purity of pure drug Acyclovir 
 
 
 
 
 
 
 
 
 
 
 
 
*All the values are expressed as mean ± SD, n = 3 
 
 
The percentage purity for Acyclovir in IP 2007 is not less than 98.0 % and not more 
than 102.0 % of the stated amount of Acyclovir. The percentage purity of Acyclovir was 
found to be 101.03 ± 0.40. So, it stands within the limits of IP 2007. 
 
S. No. Percentage Purity 
(%) 
Average Percentage Purity* 
(%) 
1. 101.35  
 
 
101.03 ± 0.40 2. 100.67 
3. 101.20 
(µg/ml) 
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S. No Percentage  LOD *Avg. percentage LOD 
1 0.320  
 
0.407±0.070 2 0.451 
3 0.483 
 
 
 
7.1.6. Loss on Drying: 
 
The percentage loss on drying after 3 hours was found to be as follows 
 
Table 20: Percentage loss on drying for Acyclovir 
 
 
 
 
 
 
 
 
 
 
 
 
                    *All values are expressed as mean± S.D., n=3 
 
The  sample  passes  test  for  loss  on  drying  as  per  the  limit  specified  in  
        IP, 2007 (N.M.T.-1) 
 
 
7.1.7: Identification and Drug polymer interaction Study 
 
a) FTIR Spectroscopy: 
 
 
                      
Figure 19: FTIR Spectrum of pure drug Acyclovir 
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                    Table 21: Characteristic frequencies in FTIR spectrum of Acyclovir 
 
S.No. Wave number (cm-
1
Inference 
1 3441.02 N-H stretching 
2 3308.74 O-H stretching 
3 3099.14 C-H stretching 
4 1717.21 C=O stretching 
5 1541.50 C=C and C=N stretching 
6 1308.75 -CH2 Wagging and twisting 
7 1216.74 Aryl alkyl ether 
8 1105.79 C-O stretching 
9 1083.93 C-O-C stretching 
 
 
The  drug  was  confirmed  as  Acyclovir  with  results  obtained  from  FTIR 
spectrum analysis. 
 
              
 
 
 
 
 
 
 
 
 
 
 
Figure 20: FTIR Spectrum of Acyclovir with Xanthan Gum 
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Figure 21: FTIR Spectrum of Acyclovir with Sodium Alginate 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: FTIR Spectrum of Acyclovir with Chitosan 
 
FTIR spectroscopy was used to ensure that no chemical interaction between the drugs 
and polymers had occurred. From the FTIR spectral Figures 19 to 22 interpretations the 
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following result was obtained. The FTIR of Acyclovir and combination of polymers shows 
intense band in the Table 22 as follows. 
Sr. 
No 
Name of the 
ingredient -C = O -COOH -NH -OH 
1. Acyclovir 1717.21 1771.95 3441.02 3308.74 
2. Acyclovir and Xanthan Gum 1716.94 1771.56 3323.54 2979.04 
3. Acyclovir and Sodium Alginate 1717.21 1771.46 3318.82 3270.05 
3. Acyclovir and Chitosan 1636.41 1742.42 3438.74 2947.85 
 
Table 22: FTIR peaks of functional groups (cm-1) 
 
 
b) Differential Scanning Calorimetry (DSC) 
 
    The compatibility and interactions between drugs and polymer were checked using DSC, 
results obtained were shown in Figure 23 to 26 
 
.Figure 23: DSC Curve of pure Acyclovir 
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                              Figure 24: DSC Curve of Acyclovir with Xanthann Gum 
 
 
 
Figure 25 DSC Curve of Acyclovir with Sodium Alginate 
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Figure 26: DSC Curve of Acyclovir with Chitosan 
 
 
            
Table 23:  Data of DSC Thermogram Parameters 
 
    
      
    DSC thermogram showed that there was no any major difference in onset temperature 
and peak temperature, Which was compared with pure drug Acyclovir thermogram shown in  
Figure 23. The  data of thermogram parameters were shown in Table 23. 
Sr. No Name of ingredients and physical   mixtures 
used in formulation 
Temperature at which peak 
obtained 
1. Acyclovir 254.750C 
2. Acyclovir with Xanthan gum 257.130C 
3. Acyclovir with Sodium Alginate 254.000C  
4. Acyclovir with Chitosan 257.320C 
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A. Physical Characterization of powder blend 
The powder blends were prepared by mixing of various ingredients mentioned in table 
no.8 and used for characterization of various flow properties of powder. 
Table 24: Flow properties of powder blend for formulations F1 to F9 
Formulation 
Code 
Angle of 
repose 
(θ)* 
Bulk density 
(gm/cm3)* 
Tapped 
density 
(gm/cm3)* 
Hausner 
ratio 
(HR)* 
Carr’s 
index 
(IC)* 
F1 21.50±0.31 0.590±0.007 0.879±0.078 1.14±0.033 12.41±0.56 
F2 20.98±0.23 0.683±0.001 0.781±0.010 1.12±0.03 11.88±2.09 
F3 20.35±0.59 0.650±0.009 0.778±0.009 1.13±0.010 10.89±1.50 
F4 22.38±0.21 0.675±0.07 0.769±0.004 1.13±0.012 10.87±0.84 
F5 22.81±0.44 0.687±0.006 0.789±0.07 1.15±0.002 11.93±0.68 
F6 21.07±0.92 0.629±0.008 0.767±0.013 1.12±0.07 12.33±1.35 
F7 20.01±0.61 0.680±0.001 0.763±0.05 1.14±0.04 11.87±1.05 
F8 20.48±0.70 0.627±0.007 0.890±0.07 1.11±0.012 12.78±1.84 
F9 21.45±1.21 0.693±0.005 0.798±0.03 1.14±0.04 13.40±1.81 
   *All the values are expressed as mean± SD, n=3. 
 
 
a) Bulk Density (BD) 
The powder blends of formulations have the bulk density ranged between                   
0.590±0.007 to 0.693±0.0005 (gm/cm3). 
 
b) Tapped bulk density (TBD) 
The powder blends of formulations have the tapped bulk density ranged between 
0.763±0.05 to 0.890±0.07 (gm/cm3). These values indicate good packing characteristics and the 
powder was not bulky. 
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Figure 27: Comparison of Physical Characteristics of Bulk density and Tapped density 
for Formulations F1 to F9 
c) Carr’s Compressibility Index 
The Carr’s index for all the formulations was found to be below 13.40% indicating 
that the powders have a excellent compressibility. 
 
Figure 28: Comparison of Physical Characteristics of Carr´s index for 
 Formulations F1 to F9 
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d) Hausner’s Ratio 
The hausner’s ratio for all the formulations was found to be <1.15, indicating good 
flow properties. 
 
Figure 29: Comparison of Physical Characteristics of Hausner’s ratio for  
Formulations F1 to F9 
 
e) Angle of repose 
The flow properties of powder were analyzed by determining angle of repose which was 
found to be between 20.01±0.61 to 22.81±0.44 indicating excellent flow property. 
 
Figure 30: Comparison of Physical Characteristics of Angle of repose for  
Formulations F1 to F9 
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7.2. EVALUATION OF SUSTANIED RELEASE MATRIX TABLET 
a) Appearance 
The tablets were observed visually and did not show any defect such as capping, chipping 
and lamination. 
 
b) Physical characteristic  
The physical characteristic of  Acyclovir sustained release matrix tablets  (F1 to F9) such 
as thickness, diameter, hardness, friability, weight variation and drug content were determined 
and results of the formulations (F1 to F9) found to be within the limits specified in official 
books.  
 
Table 25: Physico-Chemical Characterization for Formulations F1 to F 9 
*All the values are expressed as mean± SD, n=3 
 
 
Code Thickness  (mm)* 
Weight 
variation test 
(%) 
Hardness 
(kg/cm2)* 
Friability 
(%)* 
Drug content 
(%)* 
F1 3.53±0.24 345±2.30 5.77±0.50 0.43±0.07 97.56±6.64 
F2 3.48±0.027 332±2.04 5.60±0.64 0.47±0.05 100.95±6.90 
F3 3.24±0.065 351±1.90 5.58±0.37 0.49±0.08 96.32±5.92 
F4 3.84±0.064 352±2.20 5.57±0.14 0.46±0.03 97.20±5.79 
F5 3.44±0.039 351±2.12 5.66±0.54 0.47±0.05 101.11±2.65 
F6 3.54±0.051 353±1.92 5.86±0.40 0.54±0.04 97.99±5.18 
F7 3.52±0.039 352±2.09 5.83±0.25 0.53±0.09 99.14±5.37 
F8 3.57±0.053 352±2.12 5.96±0.48 0.49±0.04    99.15±4.68 
F9 3.51±0.046 350±2.03 5.78±0.37 0.46±0.05 100.11±2.38 
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c) Dimension (Thickness and Diameter) 
Thickness and diameter specifications may be set on an individual product basis. 
Excessive variation in the tablet thickness and diameter can result in problems with packaging as 
well as consumer acceptance. There were no marked variations in the thickness and diameter of 
tablets within each formulation indicating uniform behavior of granules throughout the 
compression process.  
The sizes (diameter) of the tablets of all formulations were found to be 10.00±0.0 mm. 
d) Tablet Hardness  
A difference in tablet hardness reflects difference in tablet density and porosity. In which 
turn are supposed to result in different release pattern of the drug by affecting the rate of 
penetration of dissolution fluid at the surface of the tablet and formation of gel barrier. The 
hardness of tablets was found to be in the range of 5.57±0.14 kg/cm2 to 5.96±0.48kg/cm2. This 
indicates good tablet strength 
 
 
Figure 31: Comparison Study of Tablets Thickness & Hardness for Formulations F1 to F9 
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e) Percent Friability 
Percentage friability of all the formulations was found between 0.43±0.07 to 0.54±0.04%. 
This indicated good handling property of the prepared Sustained Release tablet. 
 
Figure 32: Comparison Study of Tablets friability for Formulations F1to F9 
 
f) Weight Variation 
A tablet is designed to contain a specific amount of drug. When the average mass of the 
tablet is 350 mg the pharmacopeial limit for percentage deviation is ± 5 %. The percentage 
deviation from average tablet weight for all the tablet was found to be within the specified limits 
and hence all formulations complied with the test for weight variation according to the 
pharmacopeial specifications. 
g) Drug content of Acyclovir 
The content of active ingredients in the formulation was found to be between 96.32±5.92 
to 101.11±2.65 % w/w, which is within the specified limit as per Indian  
Pharmacopoeia 1996  (i.e. 90-110% w/w). 
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Figure 33: Comparison Study of Tablets of Drug Content for Formulations F1to F9 
 
 
h) In-Vitro Dissolution Studies 
Table 26: In-vitro drug released profile of formulation F1 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative 
% drug 
released 
0 
0.1 N HCl 
0 0 
0.5 5.09±0.12 5.09±0.12 
1 10.49±1.25 10.49±1.50 
1.5 14.22±0.23 14.23±0.25 
2 17.63±0.53 17.63±0.55 
2.5 
Phosphate  
Buffer pH 
7.4 
16.78±0.09 34.41±0.09 
3 36.55±0.14 54.18±0.14 
4 51.33±0.44 68.96±0.44 
5 69.33±2.79 86.96±2.79 
6 79.78±1.01 97.41±1.01 
7 - - 
8 - - 
9 - - 
10 - - 
11 - - 
                              *All values are expressed as mean ±SD, n=3. 
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Table 27: In-vitro drug released profile of formulation F2 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative
% drug 
released 
0 
0.1 N HCl 
0 0 
0.5 3.96±0.38 3.96±0.38 
1 7.10±0.46 7.10±0.46 
1.5 11.61±0.66 11.61±0.66 
2 13.45±0.67 13.45±0.67 
2.5 
 
18.97±1.98 32.42±1.98 
3 27.82±0.57 41.27±0.57 
4 44.64±1.64 58.09±1.64 
5 52.82±1.43 66.27±1.43 
6 63.67±1.11 77.12±1.11 
7 76.53±5.28 89.98±5.28 
8 85.42±1.26 98.87±1.26 
9 - - 
10 - - 
11 - - 
*All values are expressed as mean ±SD, n=3. 
Table 28: In-vitro drug released profile of formulation F3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*All values are expressed as mean ±SD, n=3. 
Time 
(hour
s) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulativ
e % drug 
released 
0 
0.1 N HCl 
0 0 
0.5 3.78±0.18 2.78±o.18 
1 8.13±0.69 8.13±0.69 
1.5 13.89±0.56 13.88±0.57 
2 17.56±1.08 17.56±1.09 
2.5 
Phosphate 
Buffer pH 7.4 
15.08±0.40 32.64±0.40 
3 27.95±1.08 45.51±1.08 
4 33.45±0.27 51.01±0.27 
5 56.97±0.95 74.53±0.95 
6 61.70±3.38 79.26±3.38 
7 75.15±5.61 92.71±5.61 
8 80.55±0.95 98.11±0.95 
9 - - 
10 - - 
11 - - 
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       Figure 34: In-vitro Drug Released profile curve of formulations F1 to F3 
 
 
Table 29: In-vitro drug released profile of formulation F4 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative% 
drug released 
0 
0.1 N HCl 
0 0 
0.5 4.95±0.72 4.95±0.72 
1 10.15±0.96 10.15±0.98 
1.5 15.97±0.35 15.97±0.36 
2 19.09±0.29 19.07±0.28 
2.5 
Phosphate 
Buffer pH 
7.4 
17.01±0.11 36.1±0.11 
3 22.09±0.09 41.18±0.09 
4 33.11±0.82 52.2±0.82 
5 54.29±0.65 73.38±0.65 
6 64.97±0.61 84.06±0.61 
7 71.84±0.37 90.93±0.37 
8 80.61±0.48 99.70±0.48 
9 - - 
10 - - 
11 - - 
                             *All values are expressed as mean ±SD, n=3. 
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Table 30: In-vitro drug released profile of formulation F5 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative% 
drug released 
0 
0.1 N HCl 
0 0 
0.5 3.66±0.13 3.66±0.13 
1 8.14±0.28 8.14±0.28 
1.5 12.14±0.40 12.14±0.40 
2 15.45±0.38 15.45±0.38 
2.5 
Phosphate  
Buffer pH 
7.4 
13.80±0.55 29.25±0.55 
3 34.53±0.98 49.98±0.99 
4 54.45±0.58 69.94±0.61 
5 62.13±0.50 77.58±0.22 
6 66.50±0.87 81.95±0.88 
7 73.25±0.47 88.70±0.53 
8 84.29±0.05 99.74±0.05 
9 - - 
10 - - 
11 - - 
                              *All values are expressed as mean ±SD, n=3. 
 
    
                  Table 31: In-vitro drug released profile of formulation F6 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative% 
drug released   
0 
0.1 N HCl 
0 0 
0.5 3.96±0.85 3.96±0.85 
1 6.19±0.52 6.19±0.52 
1.5 7.95±0.24 7.95±0.24 
2 12.81±1.19 12.81±1.19 
2.5 
Phosphate  
Buffer pH 
7.4 
6.35±0.25 19.16±0.25 
3 14.98±0.54 27.79±0.54 
4 26.91±1.58 39.72±1.58 
5 40.49±1.52 53.3±1.52 
6 51.71±2.32 76.04±2.32 
7 63.23±1.55 75.30±1.55 
8 71.35±0.82      84.16±0.82 
9 77.90±0.44 90.71±0.44 
10 86.50±4.74 99.31±4.74 
11 - - 
                            *All values are expressed as mean ±SD, n=3. 
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Figure 35: In-vitro drug released profile curve of formulations F4 to F6 
Table 32: In-vitro drug released profile of formulation F7 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative% 
drug released   
0 
0.1 N HCl 
0 0 
0.5 4.10±0.65 4.10±0.65 
1 8.70±0.34 8.70±0.34 
1.5 13.78±0.22 13.78±0.22 
2 17.04±0.24 17.04±0.24 
2.5 
Phosphate  
Buffer pH 
7.4 
13.52±0.87 30.56±0.87 
3 27.30±0.91 44.34±0.91 
4 41.07±1.20 58.11±1.20 
5 47.19±0.73 64.23±0.73 
6 56.45±2.29 73.49±2.29 
7 65.07±2.09 82.11±2.09 
8 76.27±0.98 93.31±0.98 
9 80.31±0.87 97.35±0.87 
10 - - 
                                 *All values are expressed as mean ±SD, n=3. 
 
ACYCLOVIR SUSTAINED RELEASE MATRIX TABLETS       RESULTS AND DISCUSSION 
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 99 
 
Table 33: In-vitro drug released profile of formulation F8 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative% 
drug released   
0 
0.1 N HCl 
0 0 
0.5 3.44±0.29 3.44±0.29 
1 6.77±0.41 6.77±0.41 
1.5 10.73±0.47 10.73±0.47 
2 12.19±0.40 12.19±0.40 
2.5 
Phosphate  
Buffer pH 
7.4 
8.63±0.39 20.82±0.39 
3 24.81±1.77 37.00±1.77 
4 33.43±1.12 45.62±1.12 
5 44.92±1.62 57.11±1.62 
6 56.95±1.04 69.14±1.04 
7 65.42±1.34 77.61±1.34 
8 75.72±0.45 87.91±0.52 
9 82.06±1.32 94.25±1.32 
10 86.31±0.91 98.50±0.91 
11 - - 
*All values are expressed as mean ±SD, n=3. 
 
Table 34: In-vitro drug released profile of formulation F9 
 
Time 
(hours) 
Dissolution 
Medium 
% Drug 
Released* 
Cumulative% 
drug released  
0 
0.1 N HCl 
0 0 
0.5 2.93±0.19 2.36±0.19 
1 5.07±0.14 5.73±0.14 
1.5 8.32±0.35 8.26±0.35 
2 11.27±1.25 11.75±1.25 
2.5 
Phosphate  
Buffer pH 
7.4 
8.84±0.35 20.11±0.35 
3 22.34±1.06 33.61±1.06 
4 34.00±0.13 45.27±0.13 
5 43.44±1.26 54.71±1.26 
6 56.99±0.73 68.26±0.73 
7 61.70±0.48 72.97±0.48 
8 70.53±0.92 81.8±0.92 
9 76.03±1.41 87.3±1.41 
10 80.88±0.42 92.15±0.42 
11 84.71±0.56 95.98±0.56 
*All values are expressed as mean ±SD, n=3. 
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Figure 36: In-vitro Drug Released profile curve of formulations F7 to F9 
 
 
 
 
 
 
 
 
 
Figure 37: In-vitro drug released profile curve for formulations F1, F4, andF7 
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Figure 38: In-vitro drug released profile curve for formulations F2, F5, and F8 
 
Figure 39: In-vitro drug released profile curve for formulations F3, F6, and F9 
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Table 35: Comparative study of In-vitro drug released profile for formulations  F1 to F9 
Time 
(hr) 
Dissolution 
Medium F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 
0.1 N HCl 
0 0 0 0 0 0 0 0 0 
0.5 5.09 3.96 2.78 4.95 3.66 3.96 4.1 3.44 2.36 
1 10.49 7.1 8.13 10.15 8.14 6.19 8.7 6.77 5.73 
1.5 14.23 11.61 13.88 15.97 12.14 7.95 13.78 10.73 8.26 
2 17.63 13.45 17.56 19.07 15.45 12.81 17.04 12.19 11.75 
2.5 
Phosphate  
Buffer pH 
7.4 
34.41 32.42 32.64 36.1 29.25 19.16 30.56 20.82 20.11 
3 54.18 41.27 45.51 41.18 49.98 27.79 44.34 37.00 33.61 
4 68.96 58.09 51.01 52.2 69.94 39.72 58.11 45.62 45.27 
5 86.96 66.27 74.53 73.38 77.58 53.3 64.23 57.11 54.71 
6 97.41 77.12 79.26 84.06 81.95 76.04 73.49 69.14 68.26 
7 - 89.98 92.71 90.93 88.7 75.3 82.11 77.61 72.97 
8 - 98.87 98.11 99.70 99.74 84.16 93.31 87.91 81.8 
9 - - - - - 90.71 97.35 94.25 87.3 
10 - - - - - 99.31 - 98.50 92.15 
11 - - - - - - - - 95.98 
 
       
 
 
Figure 40: Comparative study of In-vitro drug released curve of formulations  F1 to F9 
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Acyclovir is a water insoluble drug; its release from the matrix is largely dependent on 
the polymer swelling, drug diffusion and matrix erosion. The concentration of polymer in the 
sustained release layer was a key factor in controlling the drug release. Various sustained release 
formulations were formulated with Xanthan gum, Sodium Alginate and Chitosan polymer alone; 
polyvinyl pyrolidone as binder and lactose was used as diluents, Magnesium stearate as a 
Lubricant. 
In vitro release studies of formulations F1, F2 and F3 prepared by Xanthan gum with 
concentrations of 10%, 20%& 30% respectively, in which  the release rate of F1 was found to be 
97.41±1.01, at the 6th hour and for 98.87±1.26 F2 at the end of 8th hour and 98.11±0.95 for F3 at 
the end of 8th hour. The drug release rate was found to be slower when increasing the 
concentration of polymer (Xanthan gum). 
 In vitro release studies of formulations F4, F5 and F6 prepared by Sodium Alginate with 
concentrations of 10%, 20%& 30% respectively, in which the release rate of F4 was found to be 
99.70±0.48, at the 8th hour and for 99.74±0.05 F5 at the end of 8th hour and 99.31±4.74 for F6 at 
the end of 10th hour. The release rate was found to be retarded increasing in the concentration of 
polymer (Sodium Alginate). 
In vitro release studies of formulations F7, F8 and F9  prepared by Chitosan with 
concentrations of 10%, 20% & 30% respectively, in which the release rate of F7 was found to be 
97.35±0.87, at the 9th hour and for 98.50±0.91 F8 at the end of 10th hour and 95.98±0.56 for F9 at 
the end of 11th hour. The release rate was found to be sustained due to increased in the 
concentration of polymer (Chitosan). 
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 In vitro release studies of formulations F3, F6 and F9 prepared by with concentrations of 
30% Xanthan gum, Sodium Alginate and Chitosan shows sustained release effect of F3 
formulation 98.11±0.95 at the end of 8th hour 99.31±4.74 for F6 at the end of 10th hour and 
95.98±0.56 for F9 at the end of 11th hour.  
 From the above evaluation parameters it was concluded that the formulation F9 having a 
high percentage of drug release in a sustained manner, so the formulation F9 was selected as the 
optimized formulation. Hence the formulation F9 was selected for the further stability study. 
 
i) Data Analysis (Curve Fitting Analysis) 
Korsemeyer-Peppas model indicates that the release mechanism is not well known or 
more than one type of release phenomena could be involved. The ‘n’ value could be used to 
characterize different release mechanisms as: 
Table 36:   Different drug release mechanisms of kinetic model 
 Release exponent (n) Drug Transport Mechanism 
0.5 Fickian diffusion (Higuchi Matrix) 
0.45< n=0.89 Non- Fickian diffusion 
0.89 Case II transport 
Higher than 0.89 Super case II transport 
       
It ranges between 0.5 to 1, so it was concluded that the drug release occurred via non-
fickian diffusion, which shows that the release from initially dry, hydrophilic glassy polymers 
that swell when added to water and become rubbery show anomalous diffusion as a result of the 
rearrangement of macro molecular chains. 
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7.3 Kinetic studies 
Table 37: In-vitro Release Kinetic models for Acyclovir sustained release Matrix tablets of 
formulations (F1 to F9) 
Code 
Zero order First order Higuchi Korsemeyer- Peppas 
Best fit 
model 
R2 K0 (mg/h−1) R
2
 
K1 
(h−1) R
2
 
K 
(mgh−1/2) R
2
 n 
F1 0.968 12.810 0.913 0.2209 0.8775 26.432 0.9697 1.69 Zero order 
F2 0.969 10.982 0.956 0.1962 0.9141 26.045 0.9072 1.31 Zero order 
F3 0.985 9.801 0.931 0.1656 0.8884 22.961 0.9887 1.35 Peppas 
F4 0.983 10.005 0.936 0.1708 0.8855 23.426 0.9899 1.38 Peppas 
F5 0.976 8.965 0.895 0.1606 0.8646 21.989 0.9921 1.49 Peppas 
F6 0.972 8.424 0.913 0.1551 0.8574 21.658 0.9716 1.73 Peppas 
F7 0.988 9.288 0.955 0.1598 0.9146 23.132 0.9761 1.25 Zero order 
F8 0.985 8.961 0.942 0.1682 0.8941 23.302 0.9467 1.45 Zero order 
F9 0.981 8.289 0.958 0.1517 0.9113 22.672 0.9426 1.31 Zero order 
 
 
Figure 41: Best fit model (Zero) of formulation F1 
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Figure 42: Best fit model (Zero) of formulation F2 
 
 
 
Figure 43: Best fit model (Peppas) of formulation F3 
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Figure 44: Best fit model (Peppas) of formulation F4 
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Figure 45: Best fit model (Peppas) of formulation F5 
 
Figure 46: Best fit model (Peppas) of formulation F6 
 
 
Figure 47: Best fit model (Zero) of formulation F7 
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Figure 48: Best fit model (Zero) of formulation F8 
 
 
Figure 49: Best fit model (Zero) of formulation F9 
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To know the kinetics of the best formulations, the release data was treated according to 
different models. Drug release data of tablets was fitted in zero order equation (R2= 0.9697, 
0.9072, 0.9761, 0.9467, 0.9426 for F1, F2, F7, F8 and F9) and found release mechanism to be 
diffusion. And F3, F4, F5 and F6 are shows the Peppas (R2=0.985, 0.983, 0.976, 0.972) 
           The results of dissolution data fitted to various drug release kinetic equations.  Modal was 
found to be the best fitted in all dissolution profile having higher correlation coefficient followed 
by Zero order model and the Peppas release equation. The kinetic values obtained from different 
formulations are tabulated in table 37. Optimized formulation F9 shows the Super case II 
transport Mechanism 
 
7.4. STABILITY STUDY: 
After storage the formulation was analyzed for Physico- chemical parameters, results 
were showed in Table 25. 
 
Table 38: Stability study of formulation F9 of sustained release Acyclovir tablets at room 
temperature (25
0 
C ± 2
0 
C / 60% RH ± 5%) and Accelerated temperature (40
0 
C ± 2
0 
C / 75% RH 
± 5%).  
Parameter 
 
 
At Room temperature At  Accelerated temperature 
Initial 1
st
 
Month 
2nd 
Month 
3rd 
Month 
1st  
Month 
2nd 
Month 
3rd 
Month 
Hardness 
(kg/cm2)* 
 
5.78± 
0.37 
5.70± 
0.17 
5.63± 
0.36 
5.35± 
0.39 
5.72±  
0.040 
5.60± 
0.025 
5.37± 
0.027 
Drug 
content 
(%) 
100.11±
2.38 
100.01± 
1.65 
100.00± 
0.32 
99.87± 
0.22 
100.05± 
0.578 
99.91± 
0.375  
99.76± 
0.417 
In vitro drug 
released at 
end of 11 hr  
95.98± 
0.56 
95.39± 
0.19 
95.07± 
0.98 
95.01± 
0.68 
95.62± 
1.11 
95.35± 
0.32 
95.11± 
1.01 
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Figure 50: Comparisons of Hardness before and after stability period at room  
                         temperature (25
0 
C ± 2
0 
C / 60% RH ± 5%) 
 
 
 
 
Figure 51: Comparisons of drug content before and after stability period at room  
                       temperature (25
0 
C ± 2
0 
C / 60% RH ± 5%) 
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Figure 52: Comparisons of in vitro drug released before and after   
                  stability period at room temperature (25
0 
C ± 2
0 
C / 60% RH ± 5%). 
 
 
Figure 53: Comparisons of Hardness before and after stability period at Accelerated   
                 temperature (40
0 
C ± 2
0 
C / 75% RH ± 5%). 
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Figure 54: Comparisons of drug content before and after stability period at   
                Accelerated temperature (40
0 
C ± 2
0 
C / 75% RH ± 5%) 
 
 
Figure 55: Comparisons of in vitro drug released before and after stability period at   
                   Accelerated temperature (40
0 
C ± 2
0 
C / 75% RH ± 5%)
  
 
 
 
    SUMMARY  
AND  
CONCLUSION
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In present investigation an attempt has been made to design and develop Acyclovir 
sustained release matrix tablets using Xanthan gum, Sodium Alginate and Chitosan, as release 
retarding polymers. Acyclovir is widely used as an antiviral drug; therefore have been selected to 
prepare sustained release dosage forms. 
An ideal matrix formulation prepared with different polymers and diluents concentrations 
should release its content in a sustained profile a reasonable length of time and preferably with 
zero order kinetic. 
The active pharmaceutical ingredient Acyclovir was evaluated for its physical 
characteristics, analytical profiles and drug polymer compatibility study. The powder blend was 
prepared by mixing all ingredients in mortar and pestle. The prepared powder blend was 
evaluated for Angle of repose, Bulk density, Tapped density and Carr’s index. The results 
obtained were found to be satisfactory and within the specified limits.  
  Acyclovir sustained release tablet was prepared by using direct compression method and 
an active medicament, polymer and lubricant concentrations were optimized by various trials. 
The optimization procedures aided in the stabilization of the formula. After compression the 
following parameters of Thickness, Hardness, Weight variation, Friability, content uniformity 
and In-Vitro release studies were evaluated. 
Result of the present study demonstrated that hydrophilic polymers could be successfully 
employed for formulating sustained release matrix tablets of Acyclovir. The investigated 
sustained release matrix tablet was capable of maintaining constant plasma concentration up to 
8. SUMMARY AND CONCLUSION 
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11 hours. This can be expected to reduced the frequency of administration and decrease the dose 
dependent side effects. The efficacy and safety of Acyclovir tablet dosage form are expected to 
offer optimum therapeutic efficacy and improved patient compliance. 
In the present study the effect of types and concentration of polymer were studied on    
In-Vitro drug release. It shows that increase in concentration of polymer results in the sustained 
drug released at 11 hours. The study has revealed that by increasing concentration of polymer, 
release rate of drug was retarded and results confirmed that the released rate from hydrophilic 
matrix tablets depends on type and concentration of polymer. 
        In present studies, matrix formulation containing Chitosan was probably showed better 
drug released up to 95.98 % within 11 hours, which was the average gastrointestinal residence 
time. 
According to stability study it was found that there was no significant change in hardness, 
drug content and in vitro dissolution of optimized formulation (F9). So the formulation F9 was 
concluded best formulation among the formulations F1 to F9 were prepared 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
FUTURE      
         PROSPECTS
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The study requires attention of researcher to develop sustained drug delivery systems 
using other hydrophilic polymers. Furthermore, the study can be extended to evaluate in-vivo 
performance and also In-vitro-In-vivo correlation of the tablet. 
This dosage forms holds promise for further systems. In-vitro-In-vivo correlation (IVIVC) will 
serve as a means of modeling the human organism and of gaining a better understanding of drug 
absorption and its dependence on in vitro release process. 
 
 
 
 
9.FUTURE PROJECTS 
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